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1. INTRODUCTION 
Everything made by human hands is subject to decay. Pharmaceuticals are no 
exception to this. A drug for oral use may destabilize either during its shelf life or in 
the GIT. Two major stability problems resulting in poor bioavailability of an orally 
administered drugs are – degradation of drug in to inactive form, and because of 
interaction with one or more different components present in dosage, which form a 
complex in GIT that may be poorly soluble or unabsorbable.1 
Stability testing forms an important part of the process of drug product 
development. The purpose of stability testing is to provide evidence on how the 
quality of a drug substance or drug product varies with time under the influence of a 
variety of environmental factors such as temperature, humidity, and light, and suggest 
recommendation of storage conditions, retest periods, and shelf lives, that need to be 
established. The two main aspects of drug product,  that play an important role in 
shelf life determination are assay of active drug, and degradants generated, during the 
stability study. The assay of drug product in stability test sample needs to be 
determined using stability indicating method, as recommended by the International 
Conference on Harmonization (ICH) guidelines2 and USP 26.3  
Fixed dose combination containing Ambroxol Hydrochloride (60mg) and 
Loratadine (5mg) is available in tablet form in the market. This combination therapy 
was shown to be superior used to treat respiratory disorder and allergies condition. 
Analytical research and development of fixed dose combination is found to be very 
interesting and challenging job, hence development of stability indicating method for 
Ambroxol Hydrochloride and Loratadine in combination has been selected for the 
present  study.
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2. OBJECTIVE 
The objective of this work was the stability indicating HPLC method for simultaneous 
estimation of Ambroxol HCL and Loratadine in pharmaceutical formulation. 
Particular goals were:  
 To develop a HPLC method for simultaneous estimation of Ambroxol HCl 
and Loratadine. 
 To validate the method developed using parameters like accuracy, precision, 
linearity and range for the estimation of these drugs in pharmaceutical dosage 
form. 
 To obtain the stress degraded products of Ambroxol HCl and Loratadine by 
exposing a formulation which is under study for different stress conditions like 
acid, base, oxidative, reductive and neutral media. 
 To study the stress degradation behavior of Ambroxol HCl and Loratadine by 
analyzing the different products obtained after degradation using HPLC 
method. 
 To apply the stability indicating HPLC method for the simultaneous 
estimation of Ambroxol HCL and Loratadine, and degraded product in a 
pharmaceutical formulation. 
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3.1. DRUG PROFILE: 
 
 AMBROXOL HYDROCHLORIDE 
 
Table3.1 Drug Profile of Ambroxol Hydrochloride4, 5 
 
CAS Registry number 18683-91-5 
Generic Name Ambroxol hydrochloride 
Category  Mucolytic agent 
Dosage forms Tablets (30 mg, 60 mg) Oral liquid formulation (15 mg/5 ml) 
Brand names 
1.Acocontin 
2.Acolyt 
3.Ambrodil 
4.Cetry puls  
 
Chemical structure 
 
Chemical name 
trans-4-[(2-amino-3,5 
dibromobenzyl)amino] cyclohexanol 
hydrochloride 
Molecular formula C13H18Br2N2O,HCl 
Molecular Wt (g/mol)  414.6 
Ionization constant  7.1,8.2 
Appearance A white or yellowish crystalline powder. 
Melting Point range 235 - 240 ˚C 
Loss on Drying Not more than 0.5% 
Heavy Metals (ppm) Not more than 20 ppm 
Total  impurity Not more than 0.50% 
Residue on ignition Not more than 0.10% 
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Solubility 
Sparingly soluble in water; soluble 
in methanol; practically insoluble in   
methylene chloride. 
BCS Class  I (one) 
Indications and Uses 
 Acute and Chronic disorders of the 
respiratory tract associated with 
pathologically thickened mucus and 
impaired mucus transport. 
 Its relieving pain in acute sore throat. 
 
                                   
 LORATADINE    
             
                         Table 3.2 Drug Profile of Loratadine 6, 7  
 
CAS Registry number  79794-75-5 
Generic Name  Loratadine 
Synonyms 
 Loratadina [Spanish] 
 Loratadinum [Latin] 
Category 
 Antipruritics 
 Anti-Allergic Agents 
 Antihistamines 
 Histamine H1 Antagonists, Non-Sedating 
Dosage forms 10 mg, 30 mg, 40 mg tablet dosage forms  
Brand names 
 Claritin 
 Claritin Reditabs 
 Claritin-D 
 Claritine 
 Clarityn 
 Clarityne 
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Chemical structure 
 
Chemical name 
ethyl 4-{13-chloro-4-
azatricyclo[9.4.0.0^{3,8}]pentadeca-
1(11),3,5,7,12,14-hexaen-2-
ylidene}piperidine-1-carboxylate 
Molecular formula  C22H23ClN2O2 
Molecular Wt (g/mol)  382.883 
Ionization constant  4.9 
Appearance A white solid powder 
Melting Point range 134-136 ˚C 
Loss on Drying Not more than 0.2 
Heavy Metals (ppm) Not more than 10 
Total  impurity Not more than 0.30% 
Residue on ignition Not more than 0.1% 
Solubility very soluble in acetone, alcohol, and 
chloroform. 
BCS Class II (two) 
Therapeutic category Antihistamic Agent (H1 blocker) 
Indications and Uses  A self-medication that is used alone or in 
combination with pseudoephedrine 
sulfate for the symptomatic relief of 
seasonal allergic rhinitis.  
 Also used for the symptomatic relief of 
pruritus, erythema, and urticaria 
associated with chronic idiopathic 
urticaria in patients. 
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3.2. HIGH PERFOMANCE LIQUID CHROMATOGRAPHY 
 
Although there is spectacular advancement in the instrumental methods of 
analysis, the success or failure of such method largely depends upon how pure is 
the sample for such analysis. This is because a light impurity in analyte will lead 
to erroneous results. So large number of separation methods were discovered to 
isolate analytical species before any instrumental method is resorted. Such 
separation methods included not only chromatographic methods but the non-
chromatographic techniques like solvent extraction, ring oven; zone refining, 
froath floation, dialysis, reversed osmosis and precipitation methods. However, 
chromatographic methods have become most popular because of the simplicity 
and cost of analysis. The entire credit for popularizing chromatography technique 
for the separation goes to HPLC and advanced techniques of HPLC. 
HPLC is a physical separation technique carried out  in the liquid phase in which a 
sample is separated into its constituent components (or analytes) by distributing 
between the mobile phase (a flowing liquid) and a stationary phase (sorbents 
packed inside a column). An online detector monitors the concentration of each 
separated component in the column effluent and generates a chromatogram. 
HPLC is the most widely used analytical technique for the quantitative analysis of 
pharmaceuticals, biomolecules, polymers, and other organic compounds.9 
 Principle of High Performance Liquid Chromatography8, 9 
Normal-Phase Chromatography  
Normal-phase HPLC explores the differences in the strength of the polar 
interactions of the analytes in the mixture with the stationary phase. The stronger 
the analyte stationary phase interaction, the longer the analyte retention. As with 
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any liquid chromatography technique, NP-HPLC separation is a competitive 
process. Analyte molecules compete with the mobile-phase molecules for the 
adsorption sites on the surface of the stationary phase. The stronger the mobile-
phase interactions with the stationary phase, the lower the difference between the 
stationary-phase interactions and the analyte interactions, and thus the lower the 
analyte retention.  Mobile phases in NP-HPLC are based on nonpolar solvents 
(such as hexane, heptane, etc.) with the small addition of polar modifier (like 
methanol, ethanol). Variation of the polar modifier concentration in the mobile 
phase allows for the control of the analyte retention in the column. Typical polar 
additives are alcohols (methanol, ethanol, or isopropanol) added to the mobile 
phase in relatively small amounts. Since polar forces are the dominant type of 
interactions employed and these forces are relatively strong, even only 1 % v/v 
variation of the polar modifier in the mobile phase usually results in a significant 
shift in the analyte retention. 
 
Reversed Phase Chromatography 
As opposed to normal-phase HPLC, reversed-phase chromatography employs 
mainly dispersive forces (hydrophobic or Van der Waals interactions). The 
polarities of mobile and stationary phases are reversed, such that the surface of the 
stationary phase in RP-HPLC is hydrophobic and mobile phase is polar, where 
mainly water- based solutions are employed. RP-HPLC is by far the most popular 
mode of chromatography. Almost 90% of all analyses of low-molecular-weight 
samples are carried out using RP HPLC. One of the main drivers for its enormous 
popularity is the ability to discriminate very closely related compounds and the 
ease of variation of retention and selectivity. The origin of these advantages could 
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be explained from an energetic point of view: Dispersive forces employed in this 
separation mode are the weakest intermolecular forces, thereby making the overall 
background interaction energy in the chromatographic system very low compared 
to other separation techniques. This low background energy allows for 
distinguishing very small differences in molecular interactions of closely related 
analyte. 
Fig: 3.1 Schematic Diagram of HPLC Instrument 
HPLC, a sophistication chromatography technique is most widely used of all 
analytical separation techniques. Typical HPLC system the liquid mobile phase is 
forced through the stationary phase under pressure. It includes a solvent reservoir 
to hold the mobile phase, a pump to pressurize the mobile phase, and injector to 
allow injection of a small volume of the sample mixture under high pressure, a 
CHAPTER-3                                                                                     REVIEW OF LITERATURE 
    
 
  10 
 
column containing the bed of stationary phase, a detector to detect the presence of 
components as they exit the column, and a recorder to record the detector signal. 
 Basic Chromatographic Descriptors9, 10 
Following major descriptors are commonly used to report characteristics of the 
chromatographic column, system, and particular separation: 
1.  Capacity factor or Retention factor (k) 
2.  Efficiency (Plate number, N) 
3.   Resolution (R) 
4.   Separation factor (Selectivity, α) 
5.   Tailing factor (T) or asymmetry factor (As) 
 
1.   Capacity factor or Retention factor 
Retention factor (k) is the unit less measure of the retention of a particular 
compound in a particular chromatographic system at given conditions defined as 
     
0
0
V
VVk R  =
0
0
t
ttR 
 
Where VR is the analyte retention volume, V0 the volumes of the liquid phase in 
the chromatographic system, tR the analyte retention time, and t0 sometimes 
defined as the retention time of non-retained analyte. 
Retention factor is convenient, since it is independent of the column dimensions 
and mobile phase flow rate. Note that all other chromatographic conditions 
significantly affect analyte retention. 
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Fig: 3.2 Analyte Retention Descriptors 
2.  Efficiency (Plate number, N) 
Efficiency is the measure of the degree of peak dispersion in a particular column, 
as such it is essentially the characteristic of the column. Efficiency is expressed as 
the number of theoretical plates (N) calculated as 
    
2
16 


w
tN R  
 Where tR is the analyte retention time and w the peak width at the baseline. 
 
Fig: 3.3 Schematic Diagram of Efficiency Measurements (Number of Theoretical 
Plates in the Column) 
3. Resolution (R) 
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It is a measure of quality of separation of adjacent bands in a chromatogram; 
obviously overlapping bands have small R values. It is calculated from the width 
and retention time of two adjacent peaks. 
R= 2(t2 – t1)/w1+w2 
Where, t1 and t2 are the retention time of first and second adjacent bands; w1 and w2 
are widths at their baseline. 
Reliability of calculation is poor if R is < 1.0. 
4. Separation Factor (Selectivity) (α) 
 Selectivity (α) is the ability of chromatographic system to discriminate two 
different analytes. It is defined as the ratio of corresponding capacity factors 
   α = k2/k1 = tR2 - t0 / tR1 - t0 
5. Tailing Factor (T) or Asymmetric Factor (As) 
The tailing factor, T, a measure of peak symmetry, is unity for perfectly 
symmetrical     peaks and its value increases as tailing becomes more pronounced. 
In some cases values less than unity may be observed. As peak asymmetry 
increases and hence precision becomes less reliable. 
It is expressed as- 
T = w0.05 /2d 
w0.05 is width of peak at 5 % height and d = half of peak width at 5% peak height.  
Ideally the T value should be ≤ 2. 
 Strategy for Method Development in HPLC8-13 
Everyday many chromatographers face the need to develop a high-performance 
liquid chromatography (HPLC) separation. Method development and optimization 
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in liquid chromatography is still an attractive field of research for theoreticians 
(researchers) and attracts also a lot of interest for practical analysts. Complex 
mixtures or samples required systematic method development involving accurate 
modeling of the retention behavior of the analyte. Among all, the liquid 
chromatographic methods, the reversed phase systems based on modified silica 
offers the highest probability of successful results. However, a large number of 
(system) variables (parameters) affect the selectivity and the resolution.10 
HPLC method development follows a series of steps, which are summarized as 
below: 
Information of a sample (its physical and chemical properties), define separation 
goals 
 
Need for special HPLC procedure, sample pretreatment, etc.? 
 
Choose detector and detector settings 
 
Choose LC method; preliminary run; estimate best separation conditions 
 
Optimize separation conditions 
 
Check for problems or requirement for special procedure 
 
 
Recover purified material   Quantitative calibration    Qualitative method 
 
Validate method for release to routine laboratory 
Fig: 3.4 Steps in HPLC Method Development10 
HPLC method development is not very difficult when a literature reference for the 
same or similar compounds to be analyzed can found. 
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1) Nature of Sample10 
Before proceeding with development of method for a particular sample, it is 
absolutely essential to have detailed information about sample. What are the 
components present? Excipients and impurity present in sample must be identified. 
Some important information concerning sample are: 
1. Number of components present. 
2. Chemical structures (functionality), molecular weight, pKa and solubility of 
compounds. 
3. UV spectra of compounds. 
4. Concentration range of compounds in samples of interest. 
2) Separation Goal10 
The goals of HPLC separation need to be specified clearly. Some related questions 
that should be asked at the beginning of method development include: 
1. Is the primary goal quantitative analysis, the detection of a substance, the 
characterization of unknown sample components or the isolation of purified 
material? 
2. Is it necessary to resolve all sample components? 
3. If quantitative analysis is required, what levels of accuracy and precision are 
required? 
4. For how many different sample matrices should the method be designed? 
5. How many samples will be analyzed at one time? 
3) Sample Pre-treatment10 
Sample pre-treatment is very important in development of a new method. Most of 
sample required dilution before injection. Samples come in various forms: 
CHAPTER-3                                                                                     REVIEW OF LITERATURE 
    
 
  15 
 
1. Solution ready for injection. 
2. Solution requires dilutions, buffering and addition of an internal standard. 
3. Solid that must be dissolved or extracted. 
4. Samples that require sample pretreatment to remove interference and /or to protect 
the column or equipment from damage. 
Direct injection of the sample is preferred for its convenience and greater 
precession. Best result are obtained when concentration of sample solvent are same 
as mobile phase. Nature and concentration as samples are very important because 
concentrated analyte can damage the column. 
 
4) Detector and Detector Settings10 
Variable-wavelength ultraviolet (UV) detectors normally are the first choice, 
because of their convenience and applicability for most samples. For this reason, 
information on UV spectra can be an important aid for method development. UV 
spectra can found in the literature, estimated from chemical structures of sample 
components of interest, measured directly (if pure compounds are available), or 
obtained during HPLC separation by means of photodiode-array detector. To 
obtain better sensitivity detection should be carried out at the absorption maximum 
of the substance. Universal detection is possible at 210 nm where purity of 
acetonitrile is important. 
5) Developing the Separation14 
The first consideration when developing an HPLC method is to determine the 
solubility of the sample components. Knowing the nature of analyte will allow the 
most appropriate mode of HPLC to be selected. For the selection of a suitable 
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chromatography method for organic compounds first Reversed-phase should be 
tried, if not successful, normal-phase should be taken into consideration. 
Phase selection process should be followed as shown in figure 3.5 considering the 
sample characteristics. 
 Reversed Phase Chromatography9 
Eluent Choice 
In Reversed Phase Chromatography, acetonitrile is the preferred organic solvent 
because of low viscosity and high UV transparency (if pure); disadvantage being 
poisonous, expensive. 
Aqueous eluent preferred are water: for neutral compound, 10 mM H3PO4, pH 2.3: 
for weak to medium acids (ion suppression), 10 mM phosphate buffer, pH 4.0: for 
weak to medium acids (partly ion suppression), 5 mM phosphate buffer, pH 7.5: 
for weak to medium bases or acids in ionization form, Unknown sample should be 
analyzed first with water, then with an acid and a neutral buffer: acid and basic 
compounds can be recognized by change of retention time. 
Eluent’s Choice 
According to eluotropic sequence (the UV-transparency must be taken into 
consideration) in Normal Phase Chromatography. n-hexane/dioxane can be used 
nearly universally. Eg. amides, sulfonamides, nitro compounds, heterocycles, 
carbamates, urea and alcohols can be eluted successfully in n-hexane/dioxane 
system. 
This system equilibrates fast and is stable; the water content of the eluent has no 
influence on the retention anymore. 
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1. Weaker eluents are n-hexane/CH2Cl2 or pure n-hexane for hydrocarbons, 
compounds with non-polar groups as esters, ethers and stronger eluents as n-
hexane/ isopropanol for polar compounds as carboxylic acids. 
 
Fig: 3.5 Phase Selection Process 
 
 
Specifically, the experienced chromatographer will consider several aspects of the 
separation, as summarized in Table 3.3 
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Table: 3.3 Preferred Experimental Conditions for the Initial HPLC                                
Separation9 
Separation Variable Preferred initial choice 
Column 
Dimensions(Length × ID) 15 × 0.46 cm 
Particle Size 5µm 
Stationary Phase C8 or C18 
Mobile Phase 
Solvents A and B Buffer-Acetonitrile 
% B 80-100% 
Buffer 
(compound, pH, concentration) 
10 - 25mM Phosphate Buffer 
2.0 < pH< 3.0 
Additives(e.g., amine modifiers, 
ion-pair reagents) Do not use initially
 
Flow-rate 1.5-2.0 ml/min 
Temperature 35 – 45°C 
Sample Size 
Volume < 25 µl 
Weight < 100 µg 
 
Peak shape is often a problem, especially for basic compounds analyzed by reversed 
phase HPLC. To minimize any potential problems always use a high purity silica 
phase such as Wakosil II. These modern phases are very highly deactivated so 
secondary interactions with the support are minimal. Buffers can be used effectively 
to give sharp peaks. If peak shape remains a problem, use an organic modifier such as 
triethylamine.10 
When separating acids and bases a buffered mobile phase is recommended to 
maintain consistent retention and selectivity. For basic or cationic samples, “less 
acidic” reverse-phase columns are recommended and amine additives for the mobile 
phase may be beneficial. Optimum buffering capacity occurs at a pH equal to the pKa 
of the buffer. Beyond that, buffering capacity will be inadequate. The buffer salts 
reduce peak tailing for basic compounds by effectively masking silanols. They also 
reduce potential ion-exchange interactions with unprotonated silanols. To be most 
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effective, a buffer concentration range of 10 - 50 mM is recommended for most basic 
compounds.15 
The pH range most often used for reversed-phase HPLC is 1 - 8 and can be divided 
into low pH (1 - 4) and intermediate pH (4 - 8) ranges. Each range has a number of 
advantages. Low pH has the advantage of creating an environment in which peak 
tailing is minimized and method ruggedness is, maximized. For this reason, operating 
at low pH is recommended. Analytes may sometimes appear as broad or tailing peaks 
when the mobile phase pH is at, or near, their pKa values. A more rugged mobile 
phase pH will be at least 1 pH unit different from the analyte pKa. This shifts the 
equilibrium so that 99% of the sample will be in one form. The result is consistent 
chromatography. Dramatic changes in the retention and selectivity (peak spacing) of 
basic and acidic compounds can occur when the pH of the mobile phase is changed. 
 
Table: 3.4 System Suitability Parameters and Recommendations 
Parameter Recommendation 
Capacity Factor (k) The peak should be well resolved from other peaks  
generally k >2.0 
Repeatability RSD ≤ 1% for n ≥ 5 is desirable. 
Relative retention Not essential as long as the resolution is stated. 
Resolution (R) 
R > 2 between the peak of interest and the closest 
Eluting potential interference (impurity, excipient, 
degradation product, internal standard) etc. 
Tailing Factor (T) T  ≤ 2 
Theoretical Plates 
(N) In general should be > 2000 
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 Quantitative Analysis by HPLC15 
Quantitative column chromatography is based upon a comparison of either the 
height or the area of the analyte peak with that of one or more standards. 
 
1. Analyses Based on Peak Height 
The height of a chromatographic peak is obtained by connecting the base lines on 
either side of the peak by a straight line and measuring the perpendicular distance 
from this line to peak. It is important to note, however, that peaks height are 
inversely related to peak widths. Thus, accurate results are obtained with peak 
heights only if variations in column conditions do not alter the peak widths during 
the period required to obtain chromatogram for sample and standards. 
 2. Analyses Based on Peak Areas 
Most modern chromatographic instruments are equipped with digital electronic 
integrators that permit precise estimation of peak areas. A simple method, which 
works well for symmetric peaks of reasonable widths, is to multiply the height of 
peak by its widths at one half the peak heights. Other methods involve the use of 
planimeter or cutting out the peak and determining its weight relative to the 
weight of a known area of recorded paper. 
 3. Calibration and Standards 
The most straight forward method for quantitative analysis involves the 
preparation of series of standard solutions that appropriate the composition of the 
unknown. Chromatograms for the standards are then obtained and peak heights or 
areas are plotted as function of concentration. 
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 4. Area Normalization Method 
After integrating all significant peaks in a chromatogram, total peak area may be 
calculated. Area (%) of any individual peak is called normalized peak area. This 
technique is widely used particularly in preliminary method development. 
                % A = Area of Peak ATotal Area of Peaks ሺA + B + C + Dሻ × ͳͲͲ 
  5. Internal Standard Method 
The highest precision for quantitative chromatography is obtained by use of 
internal standard because the uncertainties introduced by sample injection are 
avoided. In this procedure, a carefully measured quantity of an internal standard 
substance is introduced in to each standard and sample, and the ratio of analyte to 
internal standard peak areas (or height) serves as the analytical parameters. 
Addition of IS is essential for the sample requiring significant pre-treatment such 
as derivatisation, extraction to reduce chances of error due to these steps as it is 
expected to mimic the behaviour of analyte in such re-treatment steps. A 
calibration curve is produced by analyzing different concentrations of the pure 
drug with constant amount of IS from the chromatogram and calculate the ratio 
(Rs) for each concentration of the analyte.                             Rs = Area of the Drug Area of the Internal Standard 
Plot this ratio against concentration of the pure drug. The slope of this plot is the 
response factor. 
 The requirements for internal standards are that; it must completely resolve peak 
(R>1.25) with no interferences. It should elute close to the compound of interest 
and behave equivalent to the compound of interest for analysis like pretreatments 
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and derivative formations. It should also be stable, unreactive with sample 
components, column packing and the mobile phase and commercially available in 
high purity. This technique gives reliable, accurate, and precise results. If the 
internal standard is truly inert, the method is useful for determining the rate of 
analyte conversion in a chemical reaction. 
3.3. ANALYTICAL METHOD VALIDATION 16-18 
Method validation, according to United States Pharmacopoeia, is performed to 
ensure that an analytical methodology is accurate, specific, reproducible, and 
rugged over the specified range that an analyte will be analyzed. Method 
validation provides an assurance of reliability during normal use and is sometime 
described as the process of providing documented evidence that the method does 
what it is intended to do. Regulated laboratories must perform method validation 
in order to be in compliance with FDA regulations. 
  I. Accuracy 
Accuracy is the measure of exactness of an analytical method, or the closeness of 
agreement between the measured value and the value that is accepted either as a 
conventional, true value or an accepted reference value. Accuracy is measured as 
the percentage of analyte recovered by assay, by spiking samples in a blind study. 
To document accuracy, the ICH guideline on methodology recommends collecting 
data from a minimum of nine determinations over a minimum of three 
concentration levels covering the specified range(for example, three 
concentrations with three replicates each). The data should be reported as the 
percentage recovery of the known, added amount, or as the difference between 
mean and true value with confidence intervals. 
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 II. Precision 
ICH defines the precision of an analytical procedure as the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability, intermediate precision 
and reproducibility. 
Repeatability expresses the precision under the same operating conditions over a 
short interval of time. Repeatability is also termed intra–assay precision. 
Intermediate precision expresses variations within laboratories, such as different 
days, different analysts, different equipment, and so forth. 
Reproducibility expresses the precision between laboratories (collaborative 
studies usually applied to standardization of methodology). 
The ICH requires repeatability to be tested from at least six replications measured 
at 100 percent of the test target concentration or from at least nine replications 
covering the complete specified range. For example, the results can be obtained at 
three concentrations with three injections at each concentration. 
III. Specificity 
Specificity is the ability to measure accurately and specifically the analyte of 
interest in the presence of other components that may be expected to be present in 
the sample matrix. It is a measure of degree of interference from such things as 
other active ingredients, excipients, impurities, and degradation products, ensuring 
that a peak response is due only to a single component, that is, that no co-elutions 
exist. Specificity is measured and documented in a separation by the resolution, 
plate count (efficiency), and tailing factor. 
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ICH divides the term specificity into two separate categories: identification and 
assay/impurity tests. For identification purposes, specificity is demonstrated by 
the ability to discriminate between compounds of closely related structures, or by 
comparison to known reference materials. For assay and impurity tests, specificity 
is demonstrated by the resolution of the two closest eluting compounds. The 
compounds are usually major component or active ingredient and an impurity. If 
the impurities are available, it must be demonstrated that the assay is unaffected 
by the presence of spiked materials (impurities and /or excipients). If impurities 
are not available, the test results are compared to a second well characterized 
procedure. For assay tests, the two results are compared; for impurity tests, the 
impurity profiles are compared head to head. 
IV. Linearity and Range 
ICH defines linearity of an analytical procedure as its ability (within a given 
range) to obtain test results that are directly proportional to the concentration 
(amount) of analyte in a sample. 
Linearity may be demonstrated directly on the test substance (by dilution of 
standard stock solution) or by separately weighing synthetic mixtures of the test 
product components. 
Linearity is determined by series of five to six injections of five or more standards 
whose concentrations span 80-120 percent of the expected concentration range. 
The response should be directly proportional to the concentration of analyte or 
proportional to the well- defined mathematical calculation. A linear regression 
equation applied to the results should have an intercept not significantly different 
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from zero. If a significant non zero intercept is obtained, it should be 
demonstrated that this has no effect on the accuracy of the method. 
Frequently, the linearity is evaluated graphically, in addition to or as an alternative 
to mathematical evaluation. The evaluation is made by visually inspecting a plot 
of single height or peak area as a function of analyte concentration. Because 
deviations from linearity are sometimes difficult to detect, two additional 
graphical procedures can be used. The first is to plot deviations from regression 
line versus the concentration or versus the logarithm of the concentration if the 
concentration range covers the several decades. For linear ranges, the deviation 
should be equally distributed between positive and negative values.  
Another approach is to divide single data by their respective concentrations, 
yielding the relative responses. A graph is plotted with the relative response on y-
axis and the corresponding concentrations on the x-axis, on a log scale. The 
obtained line should be horizontal over the full linear range. At higher 
concentrations, there will typically be a negative deviation from linearity. Parallel 
horizontal lines are drawn on the graph corresponding to, for examples, 95 percent 
and 105 percent of the horizontal line. The method is linear up to the point where 
the plotted relative response line intersect the 95 percent line. 
V. Limit of Detection 
The limit of detection is defined as the lowest concentration of the analyte in the 
sample that can be detected, though not necessarily quantitated. It is the limit test 
that specifies whether or not an analyte is above or below a certain value. LOD 
may be calculated based on the standard deviation (SD) of the response and the 
slope(S) of the calibration curve at levels approaching the LOD according to the 
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formula: LOD = 3.3(SD/S). The standard deviation of the response can be 
determined based on the standard deviation of the blank, on the residual standard 
deviation of the regression line, or the standard deviation of y- intercepts of 
regression lines. The method used to determine LOD should be documented and 
supported, and an appropriate number of samples should be analyzed at the limit 
to validate the level. 
VI. Limit of Quantitation 
The limit of quantitation (LOQ) is defined as the lowest concentration of an 
analyte in a sample that can be determined with acceptable precision and accuracy 
under the stated operational conditions of the method. The calculation is based on 
the standard deviation (SD) of the response and the slope (S) of the calibration 
curve according to the formula LOQ = 10(SD/S).Again, the standard deviation of 
the response can be determined based on the standard deviation of the blank, on 
the residual standard deviation of the regression line, or standard deviation of y-
intercepts of regression lines. As with LOD, the method used to determine LOQ 
should be documented and supported, and an appropriate number of samples 
should be analyzed at the limit to validate the level. 
VII. Ruggedness 
Ruggedness, according to the USP, is the degree of reproducibility of the results 
obtained under a variety of conditions, expressed as % relative standard deviation 
(RSD). These conditions include differences in laboratories, analyst, instruments, 
reagents, and experimental periods. 
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VIII. Robustness 
Robustness is the capacity of a method to remain unaffected by small deliberate 
variations in method parameters. The robustness of a method is evaluated by 
varying method parameters such as percentage organic solvent, pH, ionic 
strength, or temperature, and determining the effect (if any) on the results of the 
method. 
  IX. System suitability 
System suitability tests are most often applied to analytical instrumentation. 
They are designed to evaluate the components of the analytical system in order 
to show that the performance of the system meet the standards required by the 
method. They are used to verify that the resolution and reproducibility of the 
chromatographic system are adequate for the analysis to be performed. System 
suitability tests are based on the concept that the equipment, electronic, 
analytical operation and sample constituent an integral system that can be 
evaluated as a whole. 
   3.4 STABILITY INDICATING ASSAY METHOD: 19-22 
The stability-indicating assay is a method that is employed for the analysis of 
stability of samples in pharmaceutical industry. With the advent of International 
Conference on Harmonization (ICH) guidelines, the requirement of 
establishment of explicitly require conduct of forced decomposition studies 
under a variety of conditions, like pH, light, oxidation, dry heat, etc. and 
separation of drug from degradation products. The method is expected to allow 
analysis of individual degradation products.20, 21 
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Stability-indicating methods according to United States-Food and Drug 
Administration (US-FDA) stability guideline of 1987 were defined as the 
‘Quantitative analytical methods that are based on the characteristic structural, 
chemical or biological properties of each active ingredient of a drug product and 
that will distinguish each active ingredient from its degradation products so that 
the active ingredient content can be accurately measured.’ This definition in the 
draft guideline of 1998 reads as: ‘Validated quantitative analytical methods that 
can detect the changes with time in the chemical, physical, or microbiological 
properties of the drug substance and drug product, and that are specific so that 
the contents of active ingredient, degradation products, and other components of 
interest can be accurately  measured without interference. 22 
  Types of stability indicating assay method (SIAM) 20 
 a) Specific Stability Indicating Assay Method 
It can be defined as ‘A method that is able to measure unequivocally the drug(s) 
in the presence of all degradation products, in the presence of excipients and 
additives, expected to be present in the formulation.’ 
 b) Selective Stability Indicating Assay Method 
Whereas it can be defined as ‘A method that is able to measure unequivocally 
the drug(s) and all degradation products in the presence of excipients and 
additives, expected to be present in the formulation’. 
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DEVELOPMENT AND VALIDATION OF STABILITY INDICATING 
ASSAY METHODS (SIAMs):20, 23-31 
  Step I: Study of the drug structure  
Major information about the drug can be gained from the structure, by 
studying of the functional groups, their way of degradation and other key 
components. There are defined functional group categories, like amides, 
esters, lactams, lactones, etc. that undergo hydrolysis, others like thiols, 
thioethers, etc. undergo oxidation, and compounds like olefins, aryl halo 
derivatives, aryl acetic acids, and those with aromatic nitro groups, N-oxides 
undergo photo decomposition.27 
Step II: Data of physicochemical parameters of drugs 
To start with the method development, it is generally important to know 
various physicochemical parameters like pKa, log P, solubility, absorptivity 
and wavelength maximum of the drug in question. The knowledge of pKa is 
important as most of the pH- related changes in retention time depend on the 
pH of the buffer to be used in the mobile phase. The knowledge of log P of the 
drug and the identified degradation products provides good insight into the 
separation behaviour likely to be obtained on a particular stationary phase.  
Step III: Stress (forced decomposition) studies.28 
Stress testing of the drug substance can help to identify the likely degradation 
products, which can in turn help to establish the degradation pathways and the 
intrinsic stability of the molecule and validate the stability indicating power of 
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the analytical procedures used. The nature of the stress testing will depend on 
the individual drug substance and the type of drug product involved. 
Stress testing is likely to be carried out on a single batch of the drug substance. 
It should include the effect of temperatures (in 10°C increments (e.g., 50°C, 
60°C, etc.) above that for accelerated testing), humidity (e.g., 75% RH or 
greater) where appropriate, oxidation, and photolysis on the drug substance. 
The testing should also evaluate the susceptibility of the drug substance to 
hydrolysis across a wide range of pH values when in solution or suspension. 
Photostability testing should be an integral part of stress testing. The standard 
conditions for photostability testing are described in ICH Q1B. 
Examining degradation products under stress conditions is useful in 
establishing degradation pathways and developing and validating suitable 
analytical procedures. However, it may not be necessary to examine 
specifically for certain degradation products if it has been demonstrated that 
they are not formed under accelerated or long term storage conditions. Results 
from these studies will form an integral part of the information provided to 
regulatory authorities. 
Step IV: Preliminary separation studies of stressed samples30 
The stress samples so obtained are subjected to preliminary analysis to study 
the number and types of degradation products formed under various 
conditions. For doing so, the simplest way is to start with a reversed-phase 
octadecyl column, preferably a new or the one in a healthy condition. Well-
separated and good quality peaks at the outset provide better confidence 
because of the unknown nature of products formed during stressing. It should 
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be preferred to use water-methanol or water-acetonitrile as the mobile phase in 
an initial stage. 
Step V: Final method development and optimizatin31 
To separate close or co-eluting peaks, the method is optimized, by changing 
the mobile phase ratio, pH, gradient, flow rate, temperature, solvent type, and 
the column and its type. 
Step VI: Identification and characterization of degradation products  
From this data, one can do the structure elucidation of the degraded product 
study. This can be done by using model analytical technique like LC-MS, GS-
MS, H1NMR, C13NMR, IR.    
Step VI: Validation of Stability Indicating Assay Methods 
The main focus of validation is on establishment of specificity/selectivity, 
followed by other parameters like accuracy, precision, linearity, range, 
robustness, etc. The limits of detection and quantitation are also determined 
which is having application in the analysis of stability of samples of bulk drug 
for determination of its expiry period. In the second stage, when the developed 
SIAM is extended to formulations or other matrices, the emphasis gets limited 
to just prove the pertinence of the established validation parameters in the 
presence of excipients or other formulation constituents. 
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3.5. LITERATURE SURVEY 
 Krishna Veni Nagappan et al developed RP-HPLC method for simultaneous 
estimation of Ambroxol Hydrochloride and Loratidine in pharmaceutical 
formulation. The method was carried out on a Phenomenex Gemini C18 (25 
cm x 4.6 mm i.d., 5 μm) column with a mobile phase consisting of 
acetonitrile: 50mM Ammonium Acetate (50:50 v/v) at a flow rate of 1.0 
ml/min. Detection was carried out at 255 nm. Hydrochlorthiazide was used as 
an internal standard. The retention time of Ambroxol Hydrochloride, 
Loratidine and Hydrochlorthiazide was 5.419, 15.549 and 3.202 min, 
respectively. The linear ranges were from 3.0-21.0 to 0.250-1.750 µg/ml for 
Ambroxol Hydrochloride and Loratadine, respectively. The percentage 
recovery obtained for Ambroxol Hydrochloride and Loratadine were 99.78 
and 99.20%, respectively.32 
 K.A. Shaikha et al developed and validated a reversed-phase HPLC method 
for simultaneous estimation of Ambroxol hydrochloride and Azithromycin in 
tablet dosage form. The chromatographic separation was achieved on a Xterra 
RP18 (250mm×4.6mm, 5µm) analytical column. A Mixture of acetonitrile–
Dipotassium phosphate (30mM) (50:50, v/v) (pH 9.0) was used as the mobile 
phase, at a flow rate of 1.7 ml/min and detector wavelength at 215 nm. The 
retention time of Ambroxol and Azithromycin was found to be 5.0 and 11.5 
min, respectively.33 
 Krupa M. Kothekar et al developed and validated analytical method for 
quantitative determination of Levofloxacin and Ambroxol hydrochloride in a 
new tablet formulation. Chromatographic separation of the two drugs was 
achieved on a Hypersil BDS C18 column (25cm X 4.6mm, 5μm). The mobile 
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phase constituted of Buffer: Acetonitirile: Methanol (650:250:100, v/v/v) with 
triethylamine and pH adjusted to 5.2 with dilute orthophosphoric acid was 
delivered at the flow rate of 1.0 ml/min. Detection was performed at 220 nm. 
Separation was completed within 10min. The linear dynamic ranges were 
from 30–180 to 250–1500 µg/ml for Ambroxol Hydrochloride and 
Azithromycin, respectively. The percentage recovery obtained for Ambroxol 
Hydrochloride and Azithromycin were 99.40 and 99.90%, respectively. Limit 
of detection and quantification for Azithromycin were 0.8 and 2.3µg/ml, for 
Ambroxol Hydrochloride 0.004 and 0.01 µg/ml, respectively.34 
 Silvia Imre et al developed a new sensitive and selective liquid 
chromatography coupled with mass spectrometry (LC/MS/MS) method for 
quantification of Loratadine (LOR) and its active metabolite 
Descarboethoxyloratadine (DSL) in human plasma, After addition of the 
internal standard, metoclopramide. The human plasma samples (0.3 ml) were 
precipitated using acetonitrile (0.75 ml) and the centrifuged supernatants were 
partially evaporated under nitrogen at 37ºC at approximately 0.3 ml volume. 
The LOR, DSL and internal standard were separated on a reversed phase 
column (Zorbax SB-C18, 100mm×3.0mm i.d., 3.5µm) under isocratic 
conditions using a mobile phase of an 8:92 (v/v) mixture of acetonitrile and 
0.4% (v/v) formic acid in water. The flow rate was maintained at 1 ml/min and 
the column temperature was kept at 45ºC. The detection of LOR, DSL and 
internal standard was done in MRM mode using an ion trap mass spectrometer 
with electrospray positive ionization. The ion transitions were monitored as 
follows: 383→337 for LOR, 311→(259 + 294 + 282) for DSL and 
300→226.8 for internal standard.35 
CHAPTER-3                                                                                     REVIEW OF LITERATURE 
    
 
  34 
 
 Meiling Qi et al determined of Roxithromycin and Ambroxol Hydrochloride 
in a new tablet formulation by liquid Chromatography. Chromatographic 
separation of the two drugs was achieved on a DiamonsilTM C18 column 
(200mm×4.6 mm, 5µm). The mobile phase consisting of a mixture of 
acetonitrile, methanol and 0.5% ammonium acetate (39:11:50 v/v/v, pH 5.5) 
was delivered at a flow rate of 1.0 ml/min. Detection was performed at 220 
nm. Linearity, accuracy and precision were found to be acceptable over the 
concentration range of 201.2–2012.0µg/ml for Roxithromycin and 42.7–
427.0µg/ml for Ambroxol Hydrochloride, respectively.36 
 Nilgun Gunden Goger et al worked on quantitative determination of Ambroxol 
in tablets by derivative UV spectrophotometric method and HPLC. 
Determination of Ambroxol in tablets was conducted by using first-order 
derivative UV spectrophotometric method at 255 nm (n=5). Standards for the 
calibration graph ranging from 5.0 to 35.0 µg/ml were prepared from stock 
solution. The proposed method was accurate with 98.69/-100.69% range of 
recovery value and precise with coefficient of variation (CV) of 1.22. These 
results were compared with those obtained by reference methods, zero-order 
UV spectrophotometric method and reversed-phase high-performance liquid 
chromatography (HPLC) method. A reversed-phase C18 column with aqueous 
phosphate (0.01 M): acetonitrile: glacial acetic acid (59:40:1, v/v/v) (pH 3.12) 
mobile phase was used and UV detector was set to 252 nm.37 
 Hohyun Kim et al developed sensitive and selective liquid chromatographic 
method coupled with tandem mass spectrometry (LC-MS/MS) for the 
quantification of Ambroxol in human plasma. Domperidone was used as an 
internal standard. The plasma samples extracted using diethyl ether under 
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basic condition. A centrifuged upper layer was then evaporated and 
reconstituted with 200 ml methanol. The reconstituted samples were injected 
into a C18 XTerra MS column (2.1×/30mm) with 3.5 µm particle size. The 
mobile phase was composed of 20 mM ammonium acetate in 90% acetonitrile 
(pH 8.8), with flow rate at 250 µl/min. The mass spectrometer was operated in 
positive ion mode using turbo electrospray ionization. Nitrogen was used as 
the nebulizer, curtain, collision, and auxiliary gases. Using MS/MS with 
multiple reaction monitoring (MRM) mode, Ambroxol was detected without 
severe interferences from plasma matrix. Ambroxol produced a protonated 
precursor ion ([M+/H]+) at m/z 379 and a corresponding product ion at m/z 
264. And internal standard (Domperidone) produced a protonated precursor 
ion ([M+/H]+) at m/z 426 and a corresponding product ion at m/z 174. 
Detection of Ambroxol in human plasma was accurate and precise, with 
quantification limit at 0.2 ng/ml.38 
 K. Vyas et al detected three unknown impurities in Loratadine bulk drug at 
levels below 0.1% by a simple isocratic reversed-phase high performance 
liquid chromatography (HPLC). These impurities were isolated from mother 
liquor sample of Loratadine using reversed-phase preparative HPLC. Based on 
the spectral data (IR, NMR and MS) the structures of these impurities were 
characterized as 11-(N-carboethoxy-4-piperidylidene)-6,11- dihydro-5H-
benzo(5,6) cyclopenta(1,2-b)-pyridine (I), 8-bromo-11-(N-carboethoxy-4-
piperidylidene)-6,11-dihydro-5Hbenzo(5,6) cyclopenta (1,2-b)-pyridine (II) 
and 8-chloro-11-(N-carboethoxy-4-piperidylidene)-5H-benzo(5,6) cyclopenta 
(1,2-b)-pyridine (III).39 
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 Ophelia Q.P. Yin et al developed a high-performance liquid chromatographic 
(HPLC) method with fluorescence detection for the simultaneous 
determination of Loratadine (L) and its metabolite, Descarboethoxyloratadine 
(DCL), in human plasma. The linearity for L and DCL was within the 
concentration range of 0.5–16 ng/ml. The coefficient of variation of intra- and 
inter-day assay was <8.3%, with accuracy ranging from 98.3 to 105.7%. The 
lower limit of quantification was 0.5 ng/ml for both L and DCL.40 
 Satyanarayana et al studied high performance liquid chromatography (HPLC) 
and second derivative spectrophotometry for the simultaneous determination 
of Montelukast and Loratadine in pharmaceutical formulations, HPLC 
separation was achieved with a Symmetry C18 column and sodium phosphate 
buffer (pH adjusted to 3.7): acetonitrile (20:80, v/v) as eluent, at a flow rate of 
1.0 ml/min. UV detection was performed at 225 nm. 5-Methyl 2-nitrophenol 
was used as internal standard for the purpose of quantification of both the 
drugs in HPLC. In the second-order derivative spectrophotometry, for the 
determination of Loratadine the zero-crossing technique was applied at 276.1 
nm, and for Montelukast peak amplitude at 359.7 nm (tangent method) was 
used. Both methods were fully validated and comparison was made for assay 
determination of selected drugs in formulations.41 
 N.A. El Ragehy et al suggested four stability-indicating procedures have been 
suggested for determination of the non sedating antihistaminic agent 
Loratadine. Loratadine being an ester undergoes alkaline hydrolysis and the 
corresponding acid derivative was produced as a degradation product. Its 
identity was confirmed using IR and MS. The first procedure was based on 
determination of Loratadine by HPLC with detection at wavelength, 250 nm. 
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Mobile phase was acetonitrile: orthophosphoric acid (35:65) and 
benzophenone was used as an internal standard. Sensitivity range was 5.00–
50.00 µg/ml. Second determination was a densitometric procedure based on 
determination of Loratadine in the presence of its degradate at 246 nm using 
the mobile phase; Methanol: Ammonia (10:0.15). Sensitivity range was 1.25–
7.50 µg/spot. The third procedure was a spectrophotometric method where a 
mixture of Loratadine and its degradate are resolved by first derivative ratio 
spectra. Sensitivity range was found to be 3.00–22.00 µg/ml, upon carrying 
out the measurements at wavelengths 236, 262.4 and 293.2 nm. The fourth 
procedure was based on second derivative spectrophotometry, where D2 
measurements are carried out at 266 nm. The sensitivity range was 3.00–22.00 
µg/ml.42 
 Coral Barbas b and Maarit Heinanena was described for Ambroxol, trans-4-
(2-amino-3,5-dibromobenzylamino) cyclohexanol hydrochloride, and benzoic 
acid separation by HPLC with UV detection at 247 nm in a syrup as 
pharmaceutical preparation. Optimal conditions were: Column Symmetry 
Shield RPC8, 5 mm 250×4.6 µm, and methanol:(H3PO4 8.5 mM/triethylamine 
pH 2.8) 40:60 v/v.43 
 John E. Koundourellis et al described method for Ambroxol in the presence of 
different preservatives in pharmaceutical formulations. The method was 
separates used to Ambroxol from methyl- ethyl-, propyl- and butyl paraben 
and from other multi-component mixtures. The retention behaviour of 
Ambroxol and parabens as a function of both pH and mobile phase 
composition was investigated. The eluents were monitored with a UV detector 
at 247nm.44 
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 C. Barbas et al developed and validated a HPLC method employing a 
Symmetry Shield RP8 column for loratadine and related compounds 
measurement. The mobile phase consisted of methanol-buffer A (65:35, v/v), 
being buffer A: H3PO4 10 mM (H2O) brought up to pH 7.00 with 
triethylamine. UV detection was performed at 244 nm. Validation parameters 
for linearity, accuracy and precision are in agreement with ICH guidelines for 
all the analytes and that permits to consider the method reliable and suitable 
for application to long-term stability and purity studies.45 
 Grzegorz Bazylak and Luc J. Nagels developed analytical method for 
Simultaneous high-throughput determination of Clenbuterol, Ambroxol and 
Bromhexine in pharmaceutical formulations by isocratic HPLC system with 
potentiometric detection, A silica column (250×/4.6 mm i.d.) was used as a 
stationary phase with acetonitrile (ACN)-ethanol-perchloric acid (1.66 mM) 
(60:2:38, v/v/v) (pH 2.45) as mobile phase and RP18 hybrid silica polymer 
column eluted with Acetonitrile-phosphoric acid (20 mM) (25:75, v/v) (pH 
2.60).46 
 Taijun Hang et al developed a rapid, simple and sensitive LC–MS/MS method 
for simultaneous determination of amoxicillin and ambroxol in human plasma 
using clenbuterol as internal standard (IS), was performed using electrospray 
ionization. The plasma samples were subjected to a simple protein 
precipitation with methanol. Separation was achieved on a Lichrospher C18 
column (150mm×4.6mm ID, dp 5µm) using methanol (containing 0.2% of 
formic acid) and water (containing 0.2% of formic acid) as a mobile phase by 
gradient elution at a flow rate of 1.0 ml/min. Detection was performed using 
electrospray ionization in positive ion multiple reaction monitoring (MRM) 
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mode by monitoring the ion transitions from m/z 365.9→348.9 (Amoxicillin), 
m/z 378.9→263.6 (Ambroxol) and m/z 277.0→203.0 (IS). Calibration curves 
were linear in the concentration range of 5–20,000 ng/ml for Amoxicillin, and 
1–200 ng/ml for Ambroxol, with the intra- and inter-run precisions of <9% 
and the accuracies of 100±7%.47 
 M. Pospısilova et al determined expectorant drugs Ambroxol (AX) and 
Bromhexine (BX) by capillary isotachophoresis (ITP) with conductimetric 
detection. The leading electrolyte (LE) was a buffer solution that contained 5 
mM picolinic acid and 5 mM potassium picolinate (pH 5.2). The terminating 
electrolyte (TE) was 10 mM formic acid. The driving current was 80 mA 
(for:200 s) or 50 mA (for:350 s) and the detection current was 20 mA. The 
effective mobilities of AX and BX (evaluated with tetraethylammonium as the 
mobility standard) were 18.8×10-9 m2 V-1 s-1 and 14.3×10-9 m2 V-1 s-1 
respectively.48 
 Li Huande et al described a rapid, sensitive and specific method for 
determination of Ambroxol in human plasma using high performance liquid 
chromatography coupled with electrospray ionization mass spectrometry 
(HPLC–MS/ESI), Ambroxol and the internal standard (IS), fentanyl, were 
extracted from plasma by N-hexane-diethyl ether (1:1, v/v) after 
alkalinizeation with ammonia water. A centrifuged upper layer was then 
evaporated and reconstituted with 100 µl mobile phase. Chromatographic 
separation was performed on a BDS HYPERSIL C18 column (250mm×4.6 
mm, 5.0 µm, Thermoelectron corporation, USA) with the mobile phase 
consisting of 30mM ammonium acetate (0.4% formic acid)–acetonitrile 
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(64:36, v/v) at a flow-rate of 1.2 ml/min, Detection and quantitation was 
performed by the mass spectrometer.49 
 E. Satana et al described a flow-injection UV spectrophotometric method for 
the determination of Ambroxol Hydrochloride in tablets. The quantitative 
determination of Ambroxol was performed at 245 nm using distilled water as 
the carrier solvent. In this study, the flow rate, loop volume, and the number of 
injections per hour were 15 ml/min, 193μl, and 100, respectively. The 
analytical signal of Ambroxol was linear in the concentration range of 40–200 
μg/ml. The detection limit and limit of quantification were found as 11.55 and 
38.49μg/ml, respectively. A relatively high recovery value (100.4%) shows the 
accuracy of the proposed method.50 
 Weng Naidong et al developed and validated for the simultaneous analysis of 
antihistamine drug loratadine (LOR) and its active metabolite descarboethoxy-
loratadine (DCL) in human plasma using liquid chromatography with tandem 
mass spectrometric detection (LC/MS/MS), Deuterated analytes, i.e. LOR-d3 
and DCL-d3 were used as the internal standards (I.S.). Analytes were 
extracted from alkalized human plasma by liquid/liquid extraction using 
hexane. The extract was evaporated to dryness under nitrogen, reconstituted 
with 0.1% (v/v) of trifluoroacetic acid (TFA) in acetonitrile, and injected onto 
a 50×/3.0 mm i.d. 5 µm, silica column with an aqueous-organic mobile phase 
consisted of acetonitrile, water, and TFA (90:10:0.1, v/v/v). The 
chromatographic run time was 3.0 min per injection and flow rate was 0.5 
ml/min. The retention time was 1.2 and 2.0 min for LOR and DCL, 
respectively.51 
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 Isam Ismail Salem et al worked and developed a sensitive and specific liquid 
chromatography electrospray ionization ion-trap mass spectrometry (LC–ESI-
IT-MS/MS) method for the identification and quantitation of Loratadine in 
human plasma, After the addition of the internal standard (IS), plasma samples 
were extracted using isooctane: isoamyl alcohol mixture. The compounds 
were separated on a prepacked Zorbax phenyl column using a mixture of 
acetonitrile, 0.20% formic acid as mobile phase. A Finnigan LCQDUO ion-
trap mass spectrometer connected to a Waters Alliance high performance 
liquid chromatography (HPLC) was used, The method was proved to be 
sensitive and specific by testing six different plasma batches.52 
 G. Srinubabu et al developed a simple, sensitive and reliable method for 
simultaneous quantification of loratadine and desloratadine in human plasma. 
Author performed on-line coupling of extraction with Cyclone P 
50mm×0.5mm 50µm HPLC column and chromatographic separation was 
performed with Zorbax XDB C18 50mm×2.1mm 5µm, followed by 
quantification with mass detector. The method was validated and showed good 
performances in terms of linearity, sensitivity, precision, accuracy and 
stability.53 
 Abolhassan Ahmadiani et al developed a simple and rapid high-performance 
liquid chromatographic method with fluorescence detection for the 
determination of Loratadine in small volume of plasma samples. Liquid–liquid 
extraction of Loratadine and diazepam (as internal standard) from plasma 
samples was performed with n-butyl alcohol/n-hexane (2:98, v/v) in alkaline 
condition followed by back-extraction into diluted perchloric acid. 
Chromatography was carried out using a C8 column (250 × 4.6 mm, 5µm) 
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under isocratic elution with acetonitrile-20 mM sodium dihydrogen phosphate-
triethylamine (43:57:0.02, v/v/v), pH 2.4. Analyses were run at a flow-rate of 
1.0 ml/min at room temperature.54 
 M.M. Mabrouk et al described highly sensitive, simple and accurate reversed 
phase liquid chromatographic and first derivative spectrophotometric methods 
for determination of antihistaminic drug loratadine [I] and nasal decongestant 
drug pseudoephedrine sulphate. The HPLC method involves separation of [I] 
and [II] on m-BondaPak C18 column using mixture of (methanol:  H2O: 
phosphoric acid: ammonium dihydrogen phosphate) (220:300:2:3 g) 
(V/V/V/W), 60 and 40% acetonitrile as mobile phase flowing at 2 ml/min with 
ultraviolet detection at 247 nm. The spectrophotometric method is based on 
recording the first derivative spectra for [I] and [II] at 307, 266 nm, 
respectively, of their solutions in 0.1M hydrochloric acid using the acid as 
blank.55 
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4. SECTIONS OF METHODOLOGY 
4.1 APPARATUS AND EQUPIMENTS 
4.2 MATERIAL AND REAGENTS 
4.3 PREPARATION OF SOLUTIONS FOR HPLC 
4.4 RP-HPLC METHOD DEVELOPMENT AND OPTIMIZATION 
4.5 METHOD VALIDATION 
4.6 FORCED DEGRADATION STUDY  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER-4                                                                                                       METHODOLOGY 
    
 
  44 
 
4.1 APPARATUS AND EQUIPMENTS: 
 Shimadzu HPLC system 
Table 4.1 HPLC system specification 
Name Specifications 
  Pump 
  Detector 
  Data processor 
  Column 
 Rheodyne 
injector 
LC-20 AT solvent delivery system 
SPD-20A UV-Visible detector 
Spinchrome CFR version 2.4.1.93 
Phenomenex C8 (5 m, 250 mm × 4.6 mm i.d.) 
 20 µl loop 
 
Manufacturer: Shimadzu, Japan 
 Analytical Balance (Max. 200 gm-Min. 0.0001 mg)  
Model: TE 2145 
Manufacturer:  Sartorius, India. 
 Analytical Balance (Max. 300 gm-Min. 0.01 gm)  
Model: DS-852J SERIES 
Manufacturer:  ESSAE, Electronic Weighting Scale, India 
 A double beam UV-Visible spectrophotometer having two matched cells with 
1cm light path  
Model: Pharmspec-1700 
 Manufacturer: Shimadzu, Japan 
 pH Meter 
Model: 7007 
Manufacturer: Digisun electronics 
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 Hot air oven  
Model: PSM 03 
Manufacturer: Thermoelectrical co. 
 Ultrasonicator 
Model: RC-SYSTEM MU-1700 
Supplier: Servewell instruments. 
 Distillation Apparatus 
Model: VQMD 2.5L 
Manufacturer: Srinivash products 
4.2 REAGENTS AND MATERIALS: 
4.2.1 Materials: 
 Ambroxol Hydrochloride (AMH) and caffeine (CAF) - Working standard 
grade was supplied by Jugat Pharmaceutical Pvt. Ltd. (Bangalore, India) and 
its claimed purity was 99.92% and 99.82% respectively. 
 Loratadine (LOR) – working standard grade was supplied by Microlabs Ltd. 
(Bangalore, India) and its claimed purity was 99.86%. 
4.2.2 Reagents:  
 Water (HPLC grade) 
 Methanol (HPLC grade), Spectrochem 
 Orthophosphoric Acid (HPLC grade), Merck, INDIA 
 Triethylamine (HPLC grade), Merck, INDIA 
 Hydrochloric acid (35% GR), Merck, INDIA 
 Sodium hydroxide, Merck, INDIA 
 Hydrogen peroxide, Merck, INDIA 
CHAPTER-4                                                                                                       METHODOLOGY 
    
 
  46 
 
 Sodium bisulphite, Sigma Aldrich, INDIA 
4.3 PREPARATION OF SOLUTIONS FOR HPLC:   
4.3.1 Stock solution for AMH (1000g/ml): 
 An accurately weighed quantity of AMH  working/reference standard about 50 
mg was transferred into 50 ml volumetric flask and made up to mark with 
methanol (1000µg/ml). 
4.3.2 Stock solution of LOR (100g/ml) 
 An accurately weighed quantity of  LOR working/reference standard about 50 
mg was transferred into 50 ml volumetric flask and made up to mark with 
methanol (1000µg/ml). About 1ml of this solution was transferred to 10 ml 
volumetric flask and volume was made to mark with methanol (100µg/ml). 
4.3.3 Combined stock solution I of AMH (1000 µg/ml) and LOR(100 µg/ml) 
 An accurately weighed quantity of AMH working/reference standard about 50 
mg and LOR working/reference standard about 5 mg was transferred in 50ml 
volumetric flask and made up to mark with methanol. 
4.3.4 Combined stock solution II of AMH (100 µg/ml) and LOR (10 µg/ml) 
About 1ml of combined stock solution I was transferred to 10 ml volumetric 
flask and volume was made to mark with methanol. 
4.3.5 Stock solution for CAF (100 g/ml) 
 An accurately weighed quantity of CAF working/reference standard about 50 
mg was transferred into 50 ml volumetric flask. About 25 ml of water was 
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added and sonicated to dissolve. The solution was cooled to the room 
temperature and made up to mark with water. 5 ml of this solution was 
transferred to 50 ml volumetric flask and made up to mark with water to get 
concentration of 100 g/ml. 
4.3.6 Standard preparation  
For calibration curve series of dilution of drugs were prepared by transferring 
1, 2, 3, 4 and 5 ml aliquots of combine standard stock solution II and 1, 2 ml 
aliquots of combined stock solution I separately in 10 ml volumetric flasks 
along with 1ml stock solution of CAF and volume made up to mark with 
mobile phase. 
4.3.7 Sample preparation (50 g/ml): 
 10 tablets were accurately weighed and crushed. Accurately weighed about 
175.8 mg powder which contains 60 mg of AMH and 5 mg of LOR was 
transferred into 50 ml volumetric flask. About 25 ml of methanol was added 
and sonicated for 10 minutes. The solution was cooled to the room temperature 
and made up to volume with methanol. The solution was filtered through 
whatman filter paper (grade 41); filtrate was collected after discarding first few 
ml. 1 ml of this filtrate and 1 ml of stock solution of CAF (100 g/ml) were 
transferred to 10 ml volumetric flask and diluted to 10 ml with mobile phase.   
Above solution was injected into HPLC system. Peak areas were recorded for 
all the peaks. The amount of AMH and LOR present in the tablets were 
calculated using single point analysis by following equation. 
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     C1/C2 = R1/R2 
Where, C1 = Concentration of Sample Solution 
   C2 = Concentration of Standard Solution 
 R1 = Peak Area Ratio of Drug to Internal Standard for Sample Solution 
 R2 = Peak Area Ratio of Drug to Internal Standard for Standard Solution 
4.3.8 Mobile phase preparation: 
1 ml orthophosphoric acid was diluted to 1000 ml with double distilled water to 
get concentration of 0.1% OPA. About 300 ml of OPA was mixed with 700 ml 
of methanol and pH was adjusted to 5.0 with 0.1% triethylamine solution in 
methanol. Then resulting solution was filtered through 0.22 µ Supor 200 
membrane filter and degassed in sonicator for 20 minutes. This solution was 
used as mobile phase. 
4.4 RP-HPLC Method development and optimization: 
The standard solution of AMH, LOR and CAF were studied on HPLC system 
using different mobile phase composition and column to determine AMH and 
LOR in presence of degraded products. Degraded samples were prepared by 
systematic forced degradation study. These samples were used for method 
development trials to optimize the method as a stability indicating method. 
4.4.1 Selection of detection wavelength: 
The standard solutions of 10 µg/ml of AMH, LOR and CAF in methanol were 
scanned over the range of 190 nm to 400 nm wavelengths. The common 
wavelength of absorption was found to be 255 nm. So the wavelength selected 
for the determination of AMH and LOR was 255nm. 
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4.4.2 Selection of mobile phase 
Optimization can be started only after a reasonable chromatogram has been 
obtained. A reasonable chromatogram means that more or less symmetrical 
peaks on the chromatogram detect all the compounds. By slight change of the 
mobile phase composition, the position of the peaks can be predicted within the 
range of investigated changes. An optimized chromatogram was the one in 
which all the peaks are symmetrical and well separated in less run time. 
The mobile phase was selected on the basis of best separation, peak purity 
index, peak symmetry, theoretical plate etc. So, numbers of trial were taken for 
the selection of mobile phase as shown in Table 5.1/5.2/5.3. After number of 
trial Methanol: 0.1% OPA (70:30% v/v, pH adjusted to 5.0 with triethylamine 
solution) was selected. 
4.4.3 Selection of pH: 
The pH of the mobile phase was adjusted between 2.0 to 8.0 in different mobile 
phase and chromatogram was study for peak tailing, resolution between 
degraded product. So pH of mobile phase was adjusted to 5.0 with 0.1% 
triethylamine solution (HPLC grade). 
4.4.4 Selection of flow rate 
Different mobile phase flow rates (0.7, 1.0, 1.5ml/min) were investigated. The 
optimum flow rate for which the column plate number (N) was maximum, with 
the best resolution between all components and with a short run time (20min) 
was selected 
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4.4.5 Selection of Internal Standard (IS) 
The selection of IS was made on the basis of stability with drug, asymmetric 
factor, resolution and number of theoretical plates. Caffeine (10µg/ml) was 
studied to use as IS for the chromatographic procedure in different mobile 
phase composition having different pH. 
4.4.6 Finalized Chromatographic conditions: 
The finalized HPLC system specifications are shown in below table. 
Table4.2 Finalised HPLC system specification 
Parameters Specifications 
Column Phenonemex C8 (250×4.6mm, 5µm) 
Mobile phase Methanol: 0.1%OPA (70:30%v/v) 
pH of  mobile phase  5.0 using triethylamine solution (0.1%) 
IS CAF(10µg/ml) 
Flow rate(ml/min) 1.5 ml/min 
     Detection wavelength 255nm 
AUFS 0.1000 
Pressure 18.9 Mpa 
 
4.5  METHOD VALIDATION 
 Validation of RP-HPLC Method 
4.5.1  Accuracy 
 To study the accuracy, 10 tablets were weighed and powered. Analysis of the 
same was carried out as mentioned in section 4.3.7. Recovery studies were 
carried out by standard addition method by adding the known amount of AMH 
and LOR (reference standard) separately to the preanalyzed sample at three 
different concentration levels i.e. 80%, 100%, and 120% of assay concentration 
and percent recoveries were calculated. 
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 From the above filtrate about 1 ml of filtrate of sample was pipetted out and 
transferred to three 10 ml volumetric flasks separately along with this 0.96, 1.20, 
1.44 ml of aliquot from the combine stock solution I and 1 ml aliquot from 
standard caffeine solution. All the solutions were filtered through 0.45 µm 
cellulose acetate filter and injected into HPLC system. Peak areas were recorded 
for all the peaks. Peak areas ratios between AMH to CAF and LOR to CAF were 
calculated. From the above data percent recoveries were calculated and the 
accuracy study was carried out for HPLC method. 
4.5.2 Precision 
 The precision of an analytical method was studied by performing intra-day and 
inter-day precision. 
4.5.2.1  Intra-day Precision 
 Variation of results within the same day was analyzed. Intra-day precision was 
determined by analyzing the combined standard solutions of Ambroxol 
hydrochloride (20, 40, 100µg/ml) and Loratadine (2, 4, 10µg/ml) with 10 µg/ml 
of caffeine in linearity range at three different time intervals on same day. 
4.5.2.2 Inter-day Precision 
 Variation of results between the days was analyzed. Inter-day precision was 
determined by analyzing the combined standard solutions of Ambroxol 
hydrochloride (30, 50, 100µg/ml) and Loratadine (3, 5, 10µg/ml) with 10 µg/ml 
of caffeine in linearity range at three consecutive days. 
4.5.3 Repeatability 
 Combined standard solutions of AMH (50µg/ml) and LOR (5µg/ml) with 10 
µg/ml of CAF were prepared and analyzed. The solutions were analyzed six 
times and the standard deviation was calculated. 
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4.5.4 Reproducibility  
 Combined standard solutions of AMH (100 µg/ml) and LOR (10 µg/ml) with 10 
µg/ml of CAF were prepared and analyzed. Both the solutions were prepared and 
analyzed by Analyst 1 and Analyst 2, separately.  The values obtained were 
evaluated using F-test and t-test to verify their reproducibility. 
4.5.5 Linearity and Range 
 The concentration ranges of 10-200 µg/ml for AMH and 1-20 µg/ml for LOR 
were prepared and analyzed. From the data, linearity and range were determined. 
4.5.6 Limit of Detection and Limit of Quantitation  
 Detection limit and quantitation limit were determined based on the standard 
deviation of y – intercepts of six calibration curves and average slope of six 
calibration curves.    LOD= 3.3 × Standard Deviation of  y − Intercepts of Six Calibration CurvesAverage Slope of Six Calibration Curves              LOQ = ͳͲ × Standard Deviation of  y − Intercepts of Six Calibration CurvesAverage Slope of Six Calibration Curves  
4.5.7 System Suitability 
Combined standard solutions of AMH (100 µg/ml) and LOR (10 µg/ml) with 
CAF (10 µg/ml) were prepared and analyzed six times. Chromatograms were 
studied for different parameters such as tailing factor, resolution and theoretical 
plates to see that whether they complies with the recommended limit or out of 
recommended limit.  
4.5.8 Robustness 
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The effect of change in the pH of mobile phase and flow rate on the retention 
time, tailing factor, theoretical plates and resolution were studied. Combined 
standard solutions of AMH (100µg/ml), LOR (10 µg/ml) with CAF (10µg/ml) 
were prepared and analyzed at different pH (4.85, 5.00, 5.15) of the mobile phase 
and at different flow rate (1.45, 1.50, 1.54 ml/min). 
4.6 FORCED DEGRADATION STUDY: 
 In order to establish whether the analytical method for the assay was stability 
indicating, tablets, pure active pharmaceutical ingredient (API) of AMH and 
LOR were subjected to various stress conditions to conduct forced degradation 
studies. Stress studies were carried out under the conditions of acid/base 
hydrolysis, oxidation, reduction and neutral in accordance with ICH Q1A (R2) 
guideline. Several trials with different severity of each stressed conditions were 
carried out to achieve 10-30% degradation of drugs.  
4.6.1 Forced degradation studies of mixture of standard drugs :  
 For acid degradation: 
Standard of AMH (600mg) and LOR (50mg) was accurately weighed and 
transferred into three sets of 250 ml round bottom flasks. About 20 ml of HCl of 
different strengths (0.1N, 1.0N, 2N) was added to all flasks and refluxed on 
heated mantle for 6 hr at 60 ºC. 
 For basic degradation: 
 Standard of AMH (600mg) and LOR (50mg) was accurately weighed and 
transferred into three sets of 250 ml round bottom flasks. About 20 ml of NaOH 
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of different strengths (0.1N, 0.5N, 0.75N, 1.0N) was added to all flasks and 
refluxed on heated mantle for 6 hr at 60 ºC. 
 
 For peroxide degradation: 
 Standard of AMH (600mg) and LOR (50mg) was accurately weighed and 
transferred into three sets of 250 ml round bottom flasks. About 20 ml of H2O2 of 
different strengths (3%, 6% v/v) was added to all flasks and refluxed on heated 
mantle for 1 hr at 60 ºC. 
 For reduction degradation: 
Standard of AMH (600mg) and LOR (50mg) was accurately weighed and 
transferred into three sets of 250 ml round bottom flasks. About 20 ml of NaHSO3 
of different strengths (10%, 15% v/v) was added to all flasks and refluxed on heated 
mantle for 5hr at 60 ºC. 
 For neutral degradation:  
Standard of AMH (600mg) and LOR (50mg) was accurately weighed and 
transferred into three sets of 250 ml round bottom flasks. About 20 ml of water was 
added to all flasks and refluxed on heated mantle for 5 hr at 60 ºC. 
About1ml of samples were withdrawn during the degradation study at different 
period of time (15min, 30min, 45min, 1hr, 2hr, 3hr, 4hr, 5hr). About 0.1ml of 
sample was taken into 10 ml volumetric flask in a few ml of mobile phase and 
sonicated for 10 minutes, This solution was cooled to the room temperature and 
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made up to volume with mobile phase. It was filtered through 0.45 µ cellulose 
acetate filter and filtrate was used for chromatographic analysis. . 
Degradation conditions were optimized for API by study the % degradation of drug 
(10-30%) and same condition were applied for degradation of tables. 
4.6.2 Forced degradation studies of tablets: 
 For acid degradation: 
Twenty tablets were weighed, crushed and powder equivalent to 600 mg of AMH 
and 50 mg of LOR was added in three sets of 250 ml round bottom flasks. About 20 
ml of 1N HCL was added to each flask and refluxed on heated mantle for 45min at 
60 ºC. 
 For basic degradation: 
Twenty tablets were weighed, crushed and powder equivalent to 600 mg of AMH and 
50 mg of LOR was added in three sets of 250 ml round bottom flasks. About 20 ml of 
0.5N NaOH was added to each flask and refluxed on heated mantle for 1 hr at 60 ºC. 
 For peroxide degradation: 
Twenty tablets were weighed, crushed and powder equivalent to 600 mg of AMH 
and 50 mg of LOR was added in three sets of 250 ml round bottom flasks. About 20 
ml of 3% H2O2 was added to each flask and refluxed on heated mantle for 30 min at 
60 ºC. 
 For reduction degradation: 
Twenty tablets were weighed, crushed and powder equivalent to 600 mg of AMH 
and 50 mg of LOR was added in three sets of 250 ml round bottom flasks. About 20 
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ml of 10% NaHSO3 was added to each flask and refluxed on heated mantle for 4 hr 
at 60 ºC. 
 
 
 For neutral degradation: 
Twenty tablets were weighed, crushed and powder equivalent to 600 mg of AMH 
and 50 mg of LOR was added in three sets of 250 ml round bottom flasks. About 20 
ml of water was added to each flask and refluxed on heated mantle for 4 hr at 60 ºC. 
About1ml of sample was withdrawn during the degradation study at time mentioned 
earlier. About 0.1ml of sample was taken into 10 ml volumetric flask in a few ml of 
mobile phase and sonicated for 10 minutes. This solution was cooled to the room 
temperature and made up to volume with mobile phase. It was filtered through 0.45 
µ cellulose acetate filter and filtrate was used for chromatographic analysis.
  
 
   5.    RESULTS  
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5.1.1 SELECTION OF ANALYTICAL WAVELENGTH 
       
 
 Figure: 5.1 Overlain Spectra of AMH, LOR and CAF for Selection of 
Analytical   Wavelength in RP-HPLC Method 
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5.1.2 OPTIMIZATION OF CHROMATOGRAPHIC CONDITION 
    
   Table: 5.1 Results of Optimization of Chromatographic Condition 
  
   
   
 
 
Mobile Phase 
Composition 
(ACN: AA) 
%v/v 
 
pH 
 
Column 
 
Flow 
rate 
ml/min 
 
Drug 
 
Rt 
(min)
 
 
Tailing 
Factor 
 
Theoretical 
Plates 
Theoretical 
Plates/250 mm 
 
Resolution 
 
50:50 
3 C18 1 
CAF 2.743 1.118 7753 31012 -- 
AMH 3.030 0.510 2595 10380 1.586 
LOR 3.573 1.476 8121 32482 2.748 
60:40 3 C18 1 AMH 2.760 3.158 2111 4845 -- 
60:40 2 C18 1 AMH 2.763 1.063 5223 20891 -- 
60:40 7 C18 1 
AMH 3.05 1.474 7324 29295 -- 
CYPRO 4.0704 1.654 7145 28579 1.373 
LOR 10.167 1.386 11145 44581 21.159 
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                   Table: 5.2 Results of Optimization of Chromatographic Condition 
 
 
 
 
  
Mobile Phase 
Composition 
(ACN: H2O)%v/v 
 
pH 
 
Column 
 
Flow 
rate 
ml/min 
 
Drug 
 
Rt 
(min)
 
 
Tailing 
Factor 
 
Theoretical 
Plates 
Theoretical 
Plates/ 250 
mm 
 
Resolution 
60:40 2 C18 1 LOR 3.473 1.840 4641 18565 -- 
60:40 2 C18 1 
CAF 2.690 1.097 4290 17160 -- 
AMH 3.023 0.600 1507 4740 1.405 
LOR 3.370 1.905 5530 22119 1.411 
60:40 6 C18 1.2 
CAF 2.550 1.722 4796 19184 -- 
AMH 8.977 1.692 8439 33755 23.948 
LOR 16.723 0.867 2636 10544 9.172 
60:40 6.4 C18 1 
CAF 3.217 1.300 7632 30527 -- 
AMH 7.370 4.028 52 207 1.960 
LOR 11.703 2.167 9452 37807 1.896 
60:40 7 C18 1.2 
CAF 2.540 1.500 6646 13292 -- 
AMH 8.177 1.521 8959 17917 24.041 
LOR 19.793 2.997 190 7923 12.90 
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Table: 5.3 Results of Optimization of Chromatographic Condition 
 
Mobile Phase     
Composition 
(MeOH:H20 ) 
%v/v 
 
pH 
 
Column 
 
Flow 
rate 
ml/min 
 
Drug 
 
Rt 
(min)
 
 
Tailing 
Factor 
 
Theoretical 
Plates 
Theoretical 
Plates/    
250 mm 
 
Resolution 
50:50 2.5 C18 1 
CAF 2.893 1.091 1199 4796 -- 
AMH 4.093 1.892 3342 13367 4.008 
LOR 29.210 1.701 5836 23343 27.960 
50:50 2 C8 1 
CAF 4.380 1.318 4505 18020 -- 
AMH 4.610 1.500 5038 20152 1.517 
LOR 17.037 1.643 4343 17373 2.540 
70:30 8 C8 1 
CAF 3.207 2.077 3050 12200  
AMH 16.770 2.815 799 3195 10.438 
LOR 21.743 2.015 6464 25854 2.888 
70:30 5 C8 1 
CAF 3.220 1.583 4747 18989 -- 
AMH 3.670 1.607 4415 17661 2.212 
LOR 19.173 1.242 7830 31320 28.584 
70:30 5 C8 1.5 
CAF 2.163 2.000 2586 10041 -- 
AMH 2.517 1.957 2720 11567 1.968 
LOR 13.367 1.634 5134 20703 23.356 
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Figure: 5.2 Chromatogram of AMH, LOR and CAF in Acetonitrile: 
Ammonium Acetate (50:50 % v/v, pH 3.0) at Flow Rate 1 ml/min, at 255 nm 
on C18 column. 
 
 
Figure: 5.3 Chromatogram of AMH in Acetonitrile: Ammonium Acetate 
(60:40 % v/v, pH 3.0) at Flow Rate 1 ml/min, at 255 nm on C18 column. 
 
Figure: 5.4 Chromatogram of AMH in Acetonitrile: Ammonium Acetate 
(60:40 % v/v, pH 2.0) at Flow Rate 1 ml/min, at 255 nm on C18 column. 
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Figure: 5.5 Chromatogram of AMH, LOR and CYPRO in Acetonitrile: 
Ammonium Acetate (60:40 % v/v, pH 7.0) at Flow Rate 1 ml/min, at 255 nm 
on C18 column. 
 
 
Figure: 5.6 Chromatogram of LOR in Acetonitrile: Water (60:40 %v/v, pH 
2.0) at Flow Rate 1 ml/min, at 255 nm on C18 column. 
 
 
Figure: 5.7 Chromatogram of AMH, LOR and CAF in Acetonitrile: Water 
(60:40 % v/v, pH 2.0) at 1 ml/min Flow Rate, at 255 nm on C18 column. 
 
CHAPTER-5                                                                                                                 RESULTS 
    
 
 64 
 
 
Figure: 5.8 Chromatogram of AMH, LOR and CAF in Acetonitrile: Water 
(60:40 % v/v, pH 6.0) at 1.2 ml/min Flow Rate, at 255 nm on C18 column. 
 
Figure: 5.9 Chromatogram of AMH, LOR and CAF in Acetonitrile: Water 
(60:40 % v/v, pH 6.4) at 1 ml/min Flow Rate, at 255 nm on C18 column. 
 
 
Figure: 5.10 Chromatogram of AMH, LOR and CAF in Acetonitrile: 
Water (60:40 % v/v, pH 7.0) at 1.2 ml/min Flow Rate, at 255 nm on C18 
column. 
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Figure: 5.11 Chromatogram of AMH, LOR and CAF in Methanol: Water 
(50:50 % v/v, pH 2.5) at Flow Rate 1ml/min, at 255 nm on C18 column. 
 
 
Figure: 5.12 Chromatogram of AMH, LOR and CAF in Methanol: Water 
(50:50 % v/v, pH 2.0) at Flow Rate 1ml/min, at 255 nm on C18 column. 
 
 
Figure: 5.13 Chromatogram of AMH, LOR and CAF in Methanol: Water 
(70:30 % v/v, pH 8.0) at Flow Rate 1ml/min, at 255 nm on C18 column. 
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Figure: 5.14 Chromatogram of AMH, LOR and CAF in Methanol: Water 
(70:30 % v/v, pH 5.0) at Flow Rate 1ml/min, at 255 nm on C18 column. 
 
 
Figure: 5.15 Chromatogram of AMH, LOR and CAF in Methanol: Water 
(70:30 % v/v, pH 5.0) at Flow Rate 1.5ml/min, at 255 nm on C18 column. 
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5.1.2 CALIBRATION CURVE 
 
 Table: 5.4 Results of Calibration Curve of AMH 
    
 
Fig: 5.16 Calibration Curve of AMH at 255 nm for RP-HPLC Method 
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Concentration (µg/ml) 
Concentration 
(µg/ml) 
Peak Area Ratio 
±SD %RSD 
I II III IV V VI Mean 
10 0.7780 0.8900 0.7330 1.1970 1.2104 1.3007 1.0181 0.2466 4.0376 
20 1.9800 2.000 1.8230 1.9820 1.9891 1.874 1.9413 0.0740 0.6357 
30 2.6390 2.8160 2.3320 2.7350 2.6536 2.7617 2.6562 0.1722 1.0805 
40 3.1400 4.1350 3.1360 3.500 3.3122 3.4425 3.4443 0.3702 1.7913 
50 3.5380 4.8800 3.9640 4.500 4.5846 4.5507 4.3362 0.4911 1.8876 
100 8.800 8.5580 8.900 8.320 7.3873 8.3226 8.3813 0.5423 1.0784 
200 17.5300 16.2700 16.6900 16.3160 18.1204 17.2356 17.169 0.7206 0.8395 
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Fig: 5.17 Graph for Linearity Study of AMH 
 
Table: 5.5. Linear Regression Analysis of Calibration Curves for AMH 
Parameters AMH at 255 nm 
Linearity Range (μg/ml) 10-200 
Slope 0.085 
Intercept 0.0898 
Correlation Coefficient (r2) 0.9996 
LOD (μg/ml) 2.2866 
LOQ (μg/ml) 6.9299 
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 Table: 5.6 Results of Calibration Curve of LOR   
Concentration  
(µg/ml) 
Peak Area Ratio 
±SD %RSD 
I II III IV V VI Mean* 
1 0.1740 0.4750 0.6320 0.7890 1.1400 2.0300 4.0300 0.0699 4.8489 
2 0.2640 0.4600 0.5300 0.7460 1.1200 2.0270 4.1260 0.0725 2.6734 
3 0.2100 0.4950 0.6370 0.7560 0.9010 1.9460 3.5580 0.0556 1.6272 
4 0.2350 0.5100 0.5800 0.6710 0.8840 1.9210 4.0900 0.0711 1.6883 
5 0.1920 0.4620 0.5069 0.6203 0.7823 1.8900 3.0765 0.1911 3.4920 
10 0.3677 0.3093 0.5317 0.6296 0.6477 1.1595 2.8966 0.3327 3.0322 
20 0.1740 0.4750 0.6320 0.7890 1.1400 2.0300 4.0300 0.5416 2.4872 
      
 
                  
 
                Fig: 5.18 Calibration Curve of LOR at 255 nm for RP-HPLC Method 
y = 0.1796x + 0.0316 
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      Fig: 5.19 Graph for Linearity Study of LOR 
 
 
               Table: 5.7 Linear Regression Analysis of Calibration Curves for LOR 
Parameters LOR at 255 nm 
Linearity Range (μg/ml) 1-20 
Slope 0.1796 
Intercept 0.0316 
Correlation Coefficient (r2) 0.9992 
LOD (μg/ml) 0.4530 
LOQ (μg/ml) 0.8728 
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Fig.5.20 Assay of Tablet Formulation by RP-HPLC Method 
                        
 
 Table: 5.8 Results of Chromatogram of Sample Solution 
Analyte 
Retention 
Time 
(min) 
Area 
(mV.sec)  
Tailing 
Factor 
(T) 
Theoretical 
Plates (N) 
Theoretical 
Plates /250 
mm 
Resolution 
(R) 
CAF 2.183 14.836 1.500 2576 10217 -- 
AMH 2.523 148.902 1.478 2811 12890 1.987 
LOR 13.497 22.011 1.311 5077 20684 23.198 
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5.1.3 ASSAY OF MARKETED FOMULATION 
 
  Table: 5.9 Assay Results of Tablet Formulation by RP-HPLC Method 
Sr. No. 
Amount Present(mg/tab) Amount Found  (mg/tab) % Amount found 
AMH LOR AMH LOR AMH LOR 
1 60 5 61.941 4.832 103.23 96.65 
2 60 5 59.035 4.827 98.39 96.54 
3 60 5 61.352 4.919 102.25 98.38 
4 60 5 58.376 4.961 97.29 99.22 
5 60 5 58.564 4.805 97.60 96.10 
Mean 59.854 4.869 99.75 97.38 
±SD 1.6672 0.0672 2.7787 1.3455 
%RSD 2.7855 1.3817 2.7855 1.3817 
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5.2 METHOD VALIDATION  
5.2.1 ACCURACY 
 Table: 5.10. Results of Accuracy by RP-HPLC Method 
Level of  
% Recovery 
Sr. 
No. 
Label claim (µg/tab) Amount taken (µg) 
Amount of Standard 
 Drug Added (µg) 
Total Amount   Recovered  
 (µg) %Recovery 
AMH LOR AMH LOR AMH LOR AMH LOR AMH LOR 
80% 
1 60 5 120 10 96 8 94.0776 8.0501 97.9975 100.626 
2 60 5 120 10 96 8 95.1941 7.9866 99.1605 99.8329 
3 60 5 120 10 96 8 97.8800 7.9498 101.9583 99.3736 
100% 
1 60 5 120 10 120 10 120.9247 9.8190 100.7705 98.1904 
2 60 5 120 10 120 10 117.7447 10.0272 98.12058 100.2722 
3 60 5 120 10 120 10 121.0352 9.99498 100.8627 99.9498 
120% 
1 60 5 120 10 144 12 145.3941 12.0818 100.9681 100.626 
2 60 5 120 10 144 12 141.9258 11.9571 98.5596 99.8329 
3 60 5 120 10 144 12 143.3482 11.9877 99.5473 99.3736 
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 Table: 5.11 Statistical Validation Data for Accuracy 
Level of     % 
Recovery 
Mean*                        
(% Recovery) ±SD %RSD 
AMH LOR AMH LOR AMH LOR 
80% 99.7054 99.9443 
 
2.0358 
 
0.6337 
 
2.0418 
 
0.6341 
100% 99.9179 99.4710 
 
1.5572 
 
1.1207 
 
1.5585 
 
1.1267 
 
120% 99.6917 100.074 
 
1.2107 
 
0.5416 
 
1.2144 
 
0.5412 
 
       *Mean of 3 Estimations 
5.2.2 PRECESION 
Table: 5.12 Results of Intra-day Precision of AMH for RP-HPLC Method 
Concentration 
(µg/ml) 
Peak Area Ratio at Following 
Time (hr) Mean ±SD %RSD 
0 2 4 
20 1.7526 1.7839 1.793 1.7765 0.0211 1.1929 
40 3.5262 3.476 3.3938 3.4653 0.0668 1.9288 
100 4.9485 5.1078 4.9229 4.9930 0.1001 2.0064 
 
Table: 5.13 Results of Intra-day Precision of LOR for RP-HPLC Method 
Concentration 
(µg/ml) 
Peak Area Ratio at Following 
Time (hr) Mean ±SD %RSD 
0 2 4 
2 0.3578 0.3497 0.3497 0.3524 0.0046 1.3270 
4 0.7155 0.7242 0.7121 0.7172 0.0062 0.8700 
10 1.1021 1.0703 1.0484 1.0736 0.0270 2.5150 
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Table: 5.14 Results of Inter-day Precision of AMH for RP-HPLC Method 
Concentration 
(µg/ml) 
Peak Area Ratio at Following 
day Mean ±SD %RSD 
1 2 3 
20 1.6831 1.7547 1.6957 1.7111 0.0382 2.2337 
50 4.0984 4.1891 4.1964 4.1613 0.0545 1.3119 
200 16.9558 16.8600 16.8345 16.8834 0.0639 0.3788 
 
Table: 5.15 Results of Inter-day Precision of LOR for RP-HPLC Method 
Concentration 
(µg/ml) 
Peak Area Ratio at Following 
day Mean ±SD %RSD 
1 2 3 
2 0.3518 0.3494 0.3486 0.3499 0.0016 0.4759 
5 0.8837 0.9121 0.8978 0.8978 0.0142 1.5815 
20 3.5881 3.5929 3.4954 3.5588 0.0549 1.5442 
 
5.2.3 REPEATABILITY 
Table: 5.16 Results of Repeatability (RP-HPLC Method) 
 
Drugs 
 
          
Conc. 
(µg/ml) 
Peak Area Ratio ±SD %RSD 
I II III IV V VI Mean   
AMH 
30 2.539 2.547 2.543 2.689 2.670 2.522 2.5570 0.0277 1.0866 
50 4.189 4.189 4.201 4.211 4.250 4.192 4.2133 0.0323 0.7669 
LOR 
3 0.537 0.545 0.542 0.547 0.549 0.539 0.5426 0.0060 1.1107 
5 0.932 0.889 0.892 0.901 0.912 0.923 0.9023 0.0061 0.6771 
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5.2.4 REPRODUCIBILITY 
  Table: 5.17 Results of Reproducibility (RP-HPLC Method) 
Drugs 
(concn) 
(Peak Area Ratio*±SD) 
Result 
of F-test 
Result 
of t-test# Inference 
Analyst 1 Analyst 2 
AMH(50) 4.2133±0.0323 4.1994±0.0542 0.3448 0.3861 
No 
significant 
difference 
LOR (5) 0.9023±0.0061 0.8988±0.0102 0.3700 1.9891 
No 
significant 
difference 
*Mean of 3 Estimations # tabulated (standard) value is 9.00 at probability level 0.10 
 
 
 
 
5.2.1 SYSTEM SUITABILITY 
  Table: 5.18 Results of System Suitability Parameters 
Analyte 
Retention 
Time* 
(min) 
Tailing 
Factor* 
(T) 
Theoretical 
Plates* (N) 
Theoretical 
Plates* /      
250 mm 
Resolution* 
(R) 
CAF 2.173 1.895 2451 9803 -- 
AMH 2.517 1.783 2578 10312 1.942 
LOR 13.557 1.704 5028 20112 22.989 
Required limits -- T < 2 N > 2000 -- R >2 
*Mean of 6 Estimations 
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5.2.2 ROBUSTNESS 
  Table: 5.19 Result of Robustness for Variation in pH 
pH 
Analyt
e 
Retentio
n Time* 
(min) 
Tailing 
Factor 
(T) 
Theoretica
l Plates 
(N) 
Theoretical 
Plates /  250 
mm 
Resolutio
n(R) 
4.85# 
CAF 2.147 1.789 2894 11577 -- 
AMH 2.440 1.857 2681 10724 1.664 
LOR 12.557 1.772 4986 19924 22.584 
5.00# 
CAF 2.173 1.895 2451 9803 -- 
AMH 2.517 1.783 2578 10312 1.942 
LOR 13.557 1.704 5028 20112 22.989 
5.15# 
CAF 2.153 1.950 2749 10996 -- 
AMH 2.517 1.917 2732 10927 2.042 
LOR 13.830 1.202 5643 22573 24.420 
* % RSD was found to be less than 3 for each drug; #Mean of 3 Estimations   
   
            Table: 5.20 Result of Robustness for Variation in Flow Rate (ml/min) 
Flow 
Rate 
(ml/min) 
 
Analyte 
Retention 
Time* 
(min) 
Tailing 
Factor 
(T) 
Theoretical 
Plates (N) 
Theoretical 
Plates / 250 
mm 
Resolution 
(R) 
1.455# 
CAF 2.207 1.762 2378 9513 -- 
AMH 2.517 2.042 2430 9721 1.679 
LOR 13.163 1.777 4855 19418 22.224 
1.5# 
CAF 2.173 1.895 2451 9803 -- 
AMH 2.517 1.783 2578 10312 1.942 
LOR 13.557 1.704 5028 20112 22.989 
1.545# 
CAF 2.083 1.737 2573 10293 -- 
AMH 2.373 2.273 5429 9718 1.648 
LOR 12.453 1.798 4794 19177 22.164 
* % RSD was found to be less than 3 for each drug; #Mean of 3 Estimations 
CHAPTER-5                                                                                                                 RESULTS 
    
 
 78 
 
5.3 FORCED DEGRADATION STUDY 
5.3.1 ACID DEGRADATION 
 
Fig.5.21 Chromatogram of combination of standard drugs in acid     
degradation (1N HCl, 45min) 
 
Table 5.21 Result of Chromatogram of standard drug in acid degradation  
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.663 3.235 0.5 
Deg-2 2.027 17.277 1.9 
CAF 2.137 24.964 4.5 
AMH 2.427 451.460 79.7 
LOR 13.033 84.760 12.6 
 
 
Fig.5.22 Chromatogram of tablet preparation in acid degradation (1N 
HCl, 45min) 
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Table 5.22 Result of Chromatogram of tablet preparation in acid 
degradation (1N HCl, 45min) 
      
5.3.2 BASE DEGRADATION 
 
Fig.5.23 Chromatogram of combination of standard drugs in base 
degradation (1N NaOH, 60min) 
 
Table 5.23 Result of Chromatogram of standard drugs in base 
degradation  
Name Retention time (min) Area(mV.sec) %Area 
Deg-1 1.937 721.924 28.1 
CAF 2.240 88.821 4.213 
AMH 2.563 1491.374 216.273 
Deg-2 3.733 30.519 1.2 
LOR 13.480 267.031 8.5 
 
 
 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.643 33.019 4.7 
Deg-2 2.033 12.585 1.8 
CAF 2.147 28.699 4.1 
AMH 2.450 527.364 74.9 
LOR 13.123 100.517 10.9 
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Fig.5.24 Chromatogram of tablet preparation in base degradation (1N 
NaOH, 60min) 
 
Table 5.24 Result of chromatogram of tablet preparation in base 
degradation 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.897 103.061 15.3 
CAF 2.177 25.800 3.8 
AMH 2.457 436.212 64.9 
Deg-2 3.373 16.363 2.4 
Deg-3 3.520 24.754 3.7 
LOR 12.960 75.974 9.8 
         
5.3.3 OXIDATIVE DEGRADATION 
 
Fig.5.25 Chromatogram of combine of standard drugs in oxidative 
degradation (3%H2O2, 30min) 
 
CHAPTER-5                                                                                                                 RESULTS 
    
 
 81 
 
Table 5.25 Result of Chromatogram of standard drugs in oxidative 
degradation 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.943 31.022 3.6 
CAF 2.173 17.025 2.0 
AMH 2.510 360.510 70.2 
Deg-2 3.377 18.406 2.2 
Deg-3 3.633 99.092 15.4 
LOR 13.500 51.770 6.2 
 
 
          Fig.5.26 Chromatogram of tablet preparation in oxidative degradation  
(3%H2O2, 30min) 
 
Table 5.26 Result of Chromatogram of tablet preparation in oxidative 
degradation (3%H2O2, 30min) 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.920 160.155 3.3 
CAF 2.133 180.230 3.7 
AMH 2.440 3854.494 79.5 
Deg-2 3.457 131.741 2.7 
Deg-3 4.787 78.903 1.6 
Deg-4 6.533 11.129 0.2 
LOR 13.150 569.492 8.6 
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5.3.4 REDUCTIVE DEGRADATION 
 
Fig.5.27 Chromatogram of combine of standard drugs in reductive 
degradation (10%NaHSO3, 4 Hour) 
 
 
Table 5.27 Result of Chromatogram of standard drugs in reductive 
degradation 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.903 23.312 7.6 
CAF 2.177 8.712 3.5 
AMH 2.497 213.720 70.4 
Deg-2 3.370 27.179 8.9 
LOR 13.233 30.492 9.6 
 
 
Fig.5.28 Chromatogram of tablet preparation in reductive degradation  
(10%NaHSO3, 4 Hour) 
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Table 5.28 Result of Chromatogram of tablet preparation in reductive 
degradation (10%NaHSO3, 4 Hour) 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.710 8.266 0.2 
Deg-2 1.983 39.987 0.9 
CAF 2.170 144.329 3.2 
AMH 2.440 3682.386 83.8 
Deg-3 3.383 14.040 0.3 
LOR 12.970 503.66 11.2 
 
 
 
5.3.5 NEUTRAL DEGRADATION 
 
Fig.5.29 Chromatogram of combination of Standard drugs in neutral 
degradation (Water, 4 Hour) 
 
     Table 5.29 Result of Chromatogram of Standard drugs in neutral degradation 
Name Retention time (min) Area (mV.sec) %Area 
CAF 2.180 10.537 3.3 
AMH 2.470 211.110 66.5 
Deg-1 3.470 23.524 7.4 
LOR 13.173 47.788 22.6 
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Fig.5.30 Chromatogram of tablet preparation in neutral degradation 
(Water, 4 Hour) 
 
Table 5.30 Result of chromatogram of tablet preparation in neutral 
degradation (Water, 4 Hour) 
Name Retention time (min) Area (mV.sec) %Area 
Deg-1 1.873 11.324 0.3 
Deg-2 2.050 33.452 0.7 
CAF 2.173 201.990 4.5 
AMH 2.453 3658.027 68.5 
Deg-3 3.513 33.677 0.8 
LOR 13.147 901.26 24.8 
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  Table 5.31 Results of forced degradation study of mixture of standard drugs by 
proposed RP-HPLC method 
Stress condition/Strength 
duration Drugs 
% Assay of 
drugs after 
degradation 
% Degradation 
Acidic/ 1N HCl/ 45 min 
AMH 70.9193 29.0807 
LOR 75.6189 24.3811 
Basic/ 0.5N NaOH/ 60 min 
AMH 65.8462 34.1538 
LOR 66.9575 33.0425 
Oxidative/ 3% H2O2/ 30 min 
AMH 83.0405 16.9595 
LOR 67.7243 32.2757 
Reductive/ 10% NaHSO3/ 4 hr 
AMH 96.2026 3.7974 
LOR 77.9510 22.0490 
Neural/ water/ 4 hr 
AMH 78.5690 21.4310 
LOR 100 0 
 
       Table 5.32 Results of forced degradation study of tablet formulation by 
proposed RP-HPLC method 
Stress condition/Strength 
duration Drugs 
% Assay of 
drugs after 
degradation 
% Degradation 
Acidic/ 1N HCl/ 45 min 
AMH 72.0615 27.9385 
LOR 78.0057 21.9943 
Basic/ 0.5N NaOH/ 60 min 
AMH 66.3036 33.6964 
LOR 65.5841 34.4159 
Oxidative/ 3% H2O2/ 30 min 
AMH 83.8687 16.1313 
LOR 70.3743 29.6257 
Reductive/ 10% NaHSO3/ 4 hr 
AMH 100 0 
LOR 77.7208 22.2792 
Neural/ water/ 4 hr 
AMH 71.0193 28.9807 
LOR 100 0 
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6. DISCUSSION 
6.1 REVERSE PHASE HIGH PERFORMANCE LIQUID 
CROMATOGRAPHY 
6.2 METHOD VALIDATION 
6.3 FORCED DEGRADATION STUDY 
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6.1 REVERSE PHASE HIGH PERFORMANCE LIQUID 
Optimization of Chromatographic Conditions 
Mixed solution of AMH (50 µg/ml), LOR (10 µg/ml) and CAF (10 µg/ml) was 
prepared and injected into the HPLC system. The solution was analyzed using 
different mobile phases like Acetonitrile: Ammonium Acetate (50:50 and 60:40% 
v/v at pH 2.0, 3.0 and 7.0), Acetonitrile: water (60:40% v/v at pH 2.0, 3.0, 6.0, 6.4 
and 7.0) using C18 column at different flow rate such as 1.0 and 1.2 ml/min. The 
mixture of methanol and water in proportion of 50:50% v/v (pH 2) was tried for 
separation of mixture of drugs and internal standard on C18 column at different 
flow rates. The chromatogram of mixed solution of drug and internal standard was 
also studied on C8 column using methanol: 0.1% OPA(70:30 % v/v, pH 2, 5, 8) at 
different flow rate 1, 1.2, 1.5 ml/min. Retention time, peak area, tailing factor, 
theoretical plates and resolution were observed for each peak of the 
chromatogram. It was found that the Mobile Phase consisting of methanol: 0.1% 
OPA (70:30%v/v,) adjusting the  pH 5.0 with 0.1% triethylamine solution showed 
good results at flow rate of 1.5ml/min on C8 column. So, these conditions were 
selected for the analysis of the drugs. 
      Selection of Analytical Wavelength 
The standard solutions of AMH (50 µg/ml), LOR (10 µg/ml) and CAF (10 µg/ml) 
in MP were scanned in the UV region of 400 to 190 nm using mobile phase as 
blank and the overlain spectra were recorded. It was observed that all the three 
drugs observed prominently at 255 nm, hence this wavelength was used for the 
measurement of absorption. 
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Selection of pH 
The pKa value of AMH and LOR is 8.2 and 4.9 respectively. A number of pH was 
tried but more rugged mobile phase pH was to be appeared to 5.0. At this pH, 
peak tailing was minimum and resolution between degrade products and drugs 
were found to be optimum. So, pH of mobile phase was adjusted to 5.0 with 
triethylamine solution. 
Calibration 
AMH and LOR were found to be linear in the concentration range of 10-200 
µg/ml and 1-20 µg/ml, respectively. 
Assay 
Amount of drugs present in the marketed formulation (Lorfast-AM) were 
calculated using equations mentioned in the section no. 4.3.5. Amount of AMH 
and LOR were found in the range from 97.29 – 103.23% and 96.10 – 99.20%, 
respectively. 
Method Validation 
This method was validated in accordance to ICH guidelines. Recovery studies 
were carried out by standard addition method by adding the known amount of 
AMH and LOR (reference standard) to the preanalyzed sample at three different 
concentration levels i.e. 80%, 100%, and 120% of assay concentration and 
percentage recoveries were calculated. Percentage of recoveries of AMH and 
LOR were found in the range from 97.99 – 101.95% and 99.37 – 100.62%, 
respectively. Precision of the method was determined by % RSD found among 
intra-day precision, inter-day precision, repeatability. It was found to be less than 
CHAPTER-6                                                                                                        DISCUSSION 
    
 
  89 
 
3 %. Reproducibility was determined by preparing and measuring the standard 
solutions of AMH (50 µg/ml) and LOR (5 µg/ml) by Analyst 1 and Analyst 2, 
separately.  The values obtained were evaluated using F-test and t-test to verify 
their reproducibility. Calculated value for t-test was found to be less than the 
tabulated (standard) value it can calculated that no significant difference was 
observed in the result of analysis. Detection limit and quantitation limit were 
determined from the standard deviation of y – intercepts of six calibration curves 
and average slope of six calibration curves. LOD and LOQ of AMH were found to 
be 3.4866 and 10.564 µg/ml, respectively. LOD and LOQ of LOR were found to 
be 0.5806 and 1.759 µg/ml, respectively.  
 
For robustness study, the effect of change in the pH of mobile phase and flow rate 
on the retention time, tailing factor, theoretical plates and resolution were studied. 
Combined standard solutions of AMH (50µg/ml), LOR (5 µg/ml) with CAF (10 
µg/ml) were prepared and analyzed at different pH (4.85, 5.00, 5.15) of the mobile 
phase and at different flow rate (1.455, 1.500, 1.545 ml/min). Percentage RSD of 
retention time of each peak was found to be less than 1 %. 
Forced Degradation Study 
AMH and LOR were exposed to different stress conditions such as acidic, basic, 
oxidative, reductive and neutral for different strengths and refluxed on heating 
mantle for different time periods. The developed RP-HPLC method was used for 
quantitation of drug in presence of degraded products. The amount of degradation 
of both drugs were found to be in range of 10-30% at the end of 45 min in 1N 
HCl, 1 hr in 0.5N NaOH, 30 min in 3% H2O2, 4 hr in 10% w/v NaHSO3, 4 hr in 
CHAPTER-6                                                                                                        DISCUSSION 
    
 
  90 
 
water while more than 30% degradation was observed in 0.5N NaOH at end of 
1hr. So these conditions were selected for formulation degradation. There was no 
degradation found for AMH and LOR in reductive and neutral condition 
respectively. 
Based on results, obtained from the analysis of forced degradation samples using 
proposed method, it can be concluded that developed RP-HPLC method with an 
internal standard will successfully applicable for simultaneous estimation of AMH 
and LOR in presence of their degraded product in pharmaceutical formulation. 
    
 
 
7 .    CONCLUSION 
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7. Conclusion: 
The developed stability indicating RP-HPLC method was found to be simple, 
accurate, sensitive, precise, specific and rapid. This method can be applied for routine 
quantitative analysis of Ambroxol hydrochloride and Loratadine in bulk and 
pharmaceutical formulations like tablets. This method was also capable to separate the 
degradation product of both drugs hence it can be used to check quality of product 
after different storage condition and in stress degradation study. 
  
 8.     SUMMARY 
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8. SUMMARY 
An attempt has been made to develop and validate the Stability indicating HPLC 
Method for the simultaneous estimation of Ambroxol hydrochloride and Loratadine in 
pharmaceutical formulation.  
RP-HPLC Method was performed according to the chromatographic conditions 
mentioned in the following Tables. 
Table: 8.1. HPLC System 
Liquid Chromatograph Shimadzu LC–20AT 
UV–Visible Detector Shimadzu SPD–20A 
Analytical Column Phenomenex C8 (250 mm × 4.6 mm, 5 m) 
Data Processor Spinchrome CFR Software 
Injector Rheodyne – 7725i (Fixed Capacity Loop of 20 µl) 
Syringe Hamilton, 25 µl 
 
   Table: 8.2. Chromatographic Conditions 
Mobile Phase Methanol: 0.1%OPA  (60:40 % v/v) 
pH of Mobile phase 5.0 adjusted with 0.1% triethylamine solution 
Internal Standard (IS) Caffeine (10 µg/ml) 
Flow Rate 1.5 ml/min 
Detection Wavelength 255 nm 
AUFS 0.1000 
Pressure 18.9 Mpa 
 
The developed RP-HPLC method for estimation of AHM and LOR using CAF as an 
internal standard was validated in accordance with ICH guidelines. The validation 
results are summarized in table 8.3 and 8.4. 
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Table: 8.3. Summary of Linear Regression Analysis of Calibration Curves for           
AMH and LOR for RP-HPLC Method 
Parameters AMH  LOR  
Linearity Range (μg/ml) 10-200 1-20 
Slope 0.085 0.1796 
Intercept 0.0898 0.0316 
Correlation Coefficient (r2) 0.9996 0.9992 
LOD (μg/ml) 2.2866 0.4530 
LOQ (μg/ml) 6.9299 0.8728 
 
Table: 8.4. Summary of Assay Results and Validation Parameters for                                 
RP-HPLC Method 
Parameters AMH LOR 
Analysis of Tablets (% Assay) 97.29 – 103.23% 96.10 – 99.20% 
% Recovery 99.70-99.91% 99.47-100.04% 
Intra Day Precision (%RSD) 1.1929-2.0064 0.8700-2.5150 
Inter Day Precision (%RSD) 0.3788-2.2337 0.4759-1.5815 
Repeatability (±RSD) 0.7669-1.0866 0.6771-1.1107 
Reproducibility# (t-test) 0.3861 1.9891 
Robustness* (%RSD) < 3 % < 3 % 
# tabulated (standard) value is 9.00 at probability level 0.10 
Forced degradation study was performed using different stress conditions such as 
acidic, basic, oxidative, reductive and neutral for API and formulation. 
The results of forced degradation study of API and formulation were mentioned in 
following table. 
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                       Table: 8.5. Summary of Forced Degradation Study Results of API and Formulation by RP-HPLC Method 
Stress condition/Strength duration Drugs 
API Marketed formulation 
% Assay of drugs 
after degradation % Degradation 
% Assay of drugs 
after degradation 
% 
Degradation 
Acidic/ 1N HCl/ 45 min 
AMH 70.9193 29.0807 72.0615 27.9385 
LOR 75.6189 24.3811 78.0057 21.9943 
Basic/ 0.5N NaOH/ 60 min 
AMH 65.8462 34.1538 66.3036 33.6964 
LOR 66.9575 33.0425 65.5841 34.4159 
Oxidative/ 3% H2O2/ 30 min 
AMH 83.0405 16.9595 83.8687 16.1313 
LOR 67.7243 32.2757 70.3743 29.6257 
Reductive/ 10% NaHSO3/ 4 hr 
AMH 96.2026 3.7974 100 0 
LOR 77.9510 22.0490 77.7208 22.2792 
Neural/ water/ 4 hr 
AMH 78.5690 21.4310 71.0193 28.9807 
LOR 100 0 100 0 
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From present study, it can be concluded that the developed RP-HPLC method with 
the used of internal standard will be successfully applicable for simultaneous 
estimation of Ambroxol hydrochloride and Loratadine in presence of their degraded 
product in pharmaceutical industry. 
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